



(11) **EP 3 098 319 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
30.11.2016 Bulletin 2016/48

(51) Int Cl.:
C12P 13/04 ^(2006.01) **C12P 13/08** ^(2006.01)
C12N 9/00 ^(2006.01)

(21) Application number: **16171303.7**

(22) Date of filing: **25.05.2016**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME
Designated Validation States:
MA MD

- **EREMINA, Natalia Sergeevna**
117545 Moscow (RU)
- **STOYNOVA, Natalia Viktorovna**
117545 Moscow (RU)

(74) Representative: **Strehl Schübel-Hopf & Partner**
Maximilianstrasse 54
80538 München (DE)

(30) Priority: **28.05.2015 RU 2015120052**

(71) Applicant: **Ajinomoto Co., Inc.**
Tokyo 104-8315 (JP)

(72) Inventors:
• **SAMSONOV, Valery Vasilievich**
117545 Moscow (RU)

Remarks:

A request for correction 27.06.16 has been filed pursuant to Rule 139 EPC. A decision on the request will be taken during the proceedings before the Examining Division (Guidelines for Examination in the EPO, A-V, 3.).

(54) **A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE FAMILY ENTEROBACTERIACEAE HAVING AN ATTENUATED EXPRESSION OF A GSHA GENE**

(57) The present invention provides a method for producing an L-amino acid such as a branched-chain L-amino acid by fermentation using a bacterium of the family *Enterobacteriaceae*, particularly a bacterium belonging to the genus *Escherichia*, which has been modified to attenuate expression of the *gshA* gene.

EP 3 098 319 A1

Description

Background of the Invention

Technical Field

[0001] The present invention relates generally to the microbiological industry, and specifically to a method for producing L-amino acids by fermentation of a bacterium of the family *Enterobacteriaceae* that has been modified to attenuate expression of the *gshA* gene, so that production of L-amino acids is enhanced.

Background Art

[0002] Conventionally, L-amino acids are industrially produced by fermentation methods utilizing strains of microorganisms obtained from natural sources, or mutants thereof. Typically, the microorganisms are modified to enhance production yields of L-amino acids.

[0003] Many techniques to enhance L-amino acid production yields have been reported, including transformation of microorganisms with recombinant DNA (see, for example, U.S. Patent No. 4,278,765 A) and alteration of expression regulatory regions such as promoters, leader sequences, and/or attenuators, or others known to the person skilled in the art (see, for example, US20060216796 A1 and WO9615246 A1). Other techniques for enhancing production yields include increasing the activities of enzymes involved in amino acid biosynthesis and/or desensitizing the target enzymes to the feedback inhibition by the resulting L-amino acid (see, for example, WO9516042 A1, EP0685555 A1 or U.S. Patent Nos. 4,346,170 A, 5,661,012 A, and 6,040,160 A).

[0004] Another method for enhancing L-amino acids production yields is to attenuate expression of a gene or several genes that is/are involved in degradation of the target L-amino acid, genes which divert the precursors of the target L-amino acid from the L-amino acid biosynthetic pathway, genes involved in the redistribution of the carbon, nitrogen, and phosphate fluxes, and genes encoding toxins, etc.

[0005] The *gshA* gene encodes γ -glutamate-cysteine ligase which catalyzes the first of two steps in the pathway for the biosynthesis of glutathione from L-glutamate. The enzyme is feedback-inhibited by glutathione (Apontowiel P. and Berends W., Glutathione biosynthesis in *Escherichia coli* K 12. Properties of the enzymes and regulation, *Biochim. Biophys. Acta*, 1975, 399(1):1-9). An *Escherichia coli* BL21 (DE3) strain having the increased activity of serine acetyl transferase (SAT) and the *metC*, *tnaA*, *gshA* and *dfp* genes deleted was utilized in a method for L-cysteine production by fermentation of the bacterium (CN101831397 A).

[0006] However, no data has been previously reported that describes the effect from attenuating expression of the *gshA* gene on production of L-amino acids by fermentation of an L-amino acid-producing bacterium of the family *Enterobacteriaceae*.

Summary of the Invention

[0007] An aspect of the present invention is to provide a method for producing L-amino acids such as L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-citrulline, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-ornithine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine using a bacterium belonging to the family *Enterobacteriaceae*, which can belong to the genus *Escherichia* and, more specifically, to the species *Escherichia coli* (*E. coli*), and which has been modified to attenuate expression of the *gshA* gene.

[0008] This aim was achieved by the finding that attenuation of expression of the *gshA* gene on the chromosome of an L-amino acid-producing bacterium belonging to the family *Enterobacteriaceae*, which can belong to the genus *Escherichia* and, more specifically, to the species *E. coli*, confers on the bacterium a higher productivity of L-amino acids, more specifically, branched-chain L-amino acids and, in particular, but is not limited to, L-valine. Furthermore, the production yield of L-amino acids, such as, for example, branched-chain L-amino acids, including L-valine, by fermentation of the modified bacterium of the family *Enterobacteriaceae* can be increased. The *gshA* gene can be attenuated, for example, by inactivation of expression of the *gshA* gene on the chromosome of a bacterium belonging to the family *Enterobacteriaceae*, which can belong to the genus *Escherichia* and, more specifically, to the species *E. coli*. These findings have resulted in the following non-limiting aspect of the present invention.

[0009] It is one aspect of the present invention to provide a method for producing an L-amino acid comprising:

- (i) cultivating an L-amino acid-producing bacterium of the family *Enterobacteriaceae* in a culture medium to produce the L-amino acid in the culture medium, the bacterial cells, or both; and
- (ii) collecting the L-amino acid from the culture medium, the bacterial cells, or both,

wherein the bacterium has been modified to attenuate expression of a *gshA* gene.

[0010] It is a further aspect of the present invention to provide the method as described above, wherein the bacterium belongs to the genus *Escherichia*.

[0011] It is a further aspect of the present invention to provide the method as described above, wherein the bacterium is *Escherichia coli*.

[0012] It is a further aspect of the present invention to provide the method as described above, wherein the bacterium belongs to the genus *Pantoea*.

[0013] It is a further aspect of the present invention to provide the method as described above, wherein the bacterium is *Pantoea ananatis*.

[0014] It is a further aspect of the present invention to provide the method as described above, wherein the expression of the *gshA* gene is attenuated due to inactivation of the *gshA* gene.

[0015] It is a further aspect of the present invention to provide the method as described above, wherein the *gshA* gene is deleted.

[0016] It is a further aspect of the present invention to provide the method as described above, wherein the *gshA* gene is selected from the group consisting of:

(A) a DNA comprising the nucleotide sequence of SEQ ID NO: 1;

(B) a DNA comprising a variant nucleotide sequence of SEQ ID NO: 1 due to the degeneracy of the genetic code;

(C) a DNA having an identity of not less than 60% with respect to the entire nucleotide sequence of SEQ ID NO: 1, and wherein said DNA encodes a protein having an activity of γ -glutamate-cysteine ligase;

(D) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2; and

(E) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2, but which includes one or more mutations comprising substitution, deletion, insertion, or addition of one or several amino acid residues, and wherein said protein has the activity of γ -glutamate-cysteine ligase.

(F) a DNA encoding a protein having an identity of not less than 65% with respect to the entire amino acid sequence of SEQ ID NO: 2, and wherein said protein has the activity of γ -glutamate-cysteine ligase.

[0017] It is a further aspect of the present invention to provide the method as described above, wherein the L-amino acid is selected from the group consisting of an aromatic L-amino acid and a non-aromatic L-amino acid.

[0018] It is a further aspect of the present invention to provide the method as described above, wherein the aromatic L-amino acid is selected from the group consisting of L-phenylalanine, L-tryptophan, and L-tyrosine.

[0019] It is a further aspect of the present invention to provide the method as described above, wherein the non-aromatic L-amino acid is selected from the group consisting of L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-citrulline, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-ornithine, L-proline, L-serine, L-threonine, and L-valine.

[0020] It is a further aspect of the present invention to provide the method as described above, wherein the L-amino acid is a branched-chain L-amino acid.

[0021] It is a further aspect of the present invention to provide the method as described above, wherein the branched-chain L-amino acid is selected from the group consisting of L-isoleucine, L-leucine, and L-valine.

[0022] It is a further aspect of the present invention to provide the method as described above, wherein the L-amino acid is L-valine.

Description of the Embodiments

[0023] The present invention is described in detail below.

1. Bacterium

[0024] Any L-amino acid-producing bacterium belonging to the family *Enterobacteriaceae* and modified to attenuate expression of the *gshA* gene can be used. The phrase "an L-amino acid-producing bacterium" can mean a bacterium of the family *Enterobacteriaceae* that has an ability to produce, excrete or secrete, and/or cause accumulation of an L-amino acid in a culture medium and/or the bacterial cells when the bacterium is cultured in the medium.

[0025] The phrase "an L-amino acid-producing bacterium" can also mean a bacterium that is able to produce, excrete or secrete, and/or cause accumulation of an L-amino acid in a culture medium in an amount larger than a wild-type or parental strain, such as *E. coli* K-12. The phrase "an L-amino acid-producing bacterium" can also mean a bacterium that is able to cause accumulation in a culture medium of an amount, for example, not less than 0.1 g/L, not less than 0.5 g/L, or not less than 1.0 g/L of the target L-amino acid.

[0026] Furthermore, the bacterium belonging to the family *Enterobacteriaceae* and modified to attenuate expression

of the *gshA* gene, which has an ability to produce L-amino acid, can also be used. The bacterium may inherently have the L-amino acid-producing ability or may be modified to have an L-amino acid-producing ability by using a mutation method or DNA recombination techniques. The bacterium can be obtained by attenuating expression of the *gshA* gene in a bacterium that inherently has the ability to produce an L-amino acid, or in a bacterium that has been already imparted with the ability to produce an L-amino acid. Alternatively, the bacterium can be obtained by imparting the ability to produce an L-amino acid to a bacterium already modified to attenuate expression of the *gshA* gene. Also, the bacterium can be a bacterium that has acquired the ability to produce an L-amino acid by attenuating expression of the *gshA* gene.

[0027] The phrase "L-amino acid-producing ability" can mean the ability of the bacterium to produce, excrete or secrete, and/or cause accumulation of the L-amino acid in a culture medium and/or the bacterial cells to such a level that the L-amino acid can be collected from the culture medium and/or the bacterial cells, when the bacterium is cultured in the medium.

[0028] The bacterium can produce either one kind of amino acid solely, or a mixture of two or more kinds of amino acids. Specifically, the bacterium can produce either one kind of L-amino acid solely, or a mixture of two or more kinds of L-amino acids.

[0029] The phrase "amino acid" can mean an organic compound containing at least one amino group (NH₂) and at least one carboxyl group (COOH). An L-amino acid is a non-limiting example of an amino acid.

[0030] The phrase "L-amino acid" can mean L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-citrulline, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-ornithine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine.

[0031] The phrase "aromatic L-amino acid" includes, for example, L-phenylalanine, L-tryptophan, and L-tyrosine. Because L-histidine has an aromatic moiety, specifically, an imidazole ring, the phrase "aromatic L-amino acid" can also include, besides the aforementioned aromatic L-amino acids, L-histidine.

[0032] The phrase "non-aromatic L-amino acid" includes, for example, L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-citrulline, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-ornithine, L-proline, L-serine, L-threonine, and L-valine. Because the biosynthetic pathway of L-histidine is different from the biosynthetic pathways of common aromatic amino acids such as L-phenylalanine, L-tryptophan, and L-tyrosine, the phrase "non-aromatic L-amino acid" can also include, besides the aforementioned non-aromatic L-amino acids, L-histidine.

[0033] That is, L-histidine can be included in either one of, or both of "aromatic L-amino acid" and "non-aromatic L-amino acid".

[0034] An L-amino acid can belong to one or more L-amino acid families. As an example, the glutamate family includes L-arginine, L-glutamic acid, L-glutamine, and L-proline; the serine family includes L-cysteine, glycine, and L-serine; the aspartate family includes L-asparagine, L-aspartic acid, L-isoleucine, L-lysine, L-methionine, and L-threonine; the pyruvate family includes L-alanine, L-isoleucine, L-leucine, and L-valine; and the aromatic family includes L-phenylalanine, L-tryptophan, and L-tyrosine. As an L-amino acid can be an intermediate in a biosynthetic pathway of another L-amino acid, the aforementioned families of amino acids may also include other L-amino acids, such as, for example, non-proteinogenic L-amino acids. For example, L-citrulline and L-ornithine are amino acids from the L-arginine biosynthetic pathway. Therefore, the glutamate family may include L-citrulline and L-ornithine, as well as L-arginine, L-glutamic acid, L-glutamine, and L-proline.

[0035] An L-amino acid can also belong to one or more L-amino acid groups. As an example, L-isoleucine, L-leucine, and L-valine can belong to the group of branched-chain L-amino acids. Moreover, L-homoleucine and L-homoisoleucine may also belong to the group of branched-chain L-amino acids.

[0036] L-Alanine, L-isoleucine, L-leucine, L-valine, L-homoleucine, and L-homoisoleucine are particular examples of L-amino acid. L-Alanine, L-isoleucine, L-leucine, and L-valine are specific examples of L-amino acid. L-isoleucine, L-leucine, and L-valine are more specific examples of L-amino acid. L-Valine is still more specific example of L-amino acid.

[0037] The phrase "L-amino acid" can refer not only to an amino acid in a free form, but may also include a salt or a hydrate of the amino acid, or an adduct formed by the amino acid and another organic or inorganic compound. Examples of salts of amino acids include, for example, sulfates, chlorides, carbonates, ammonium salts, sodium salts, potassium salts, and hydrochlorides. Specific examples of salts of amino acids include, but are not limited to, monochlorhydrate salt of L-lysine (L-lysine-HCl) and monochlorhydrate salt of L-arginine (L-arginine-HCl). Examples of hydrates of amino acids include, for example, monohydrates and dihydrates. A specific example of a hydrate of an amino acid includes L-cysteine monohydrate (L-Cys·H₂O).

[0038] The bacteria belonging to the family *Enterobacteriaceae* can be from the genera *Enterobacter*, *Erwinia*, *Escherichia*, *Klebsiella*, *Morganella*, *Pantoea*, *Photobacterium*, *Providencia*, *Salmonella*, *Yersinia*, and so forth, and can have the ability to produce an L-amino acid. Specifically, those classified into the family *Enterobacteriaceae* according to the taxonomy used in the NCBI (National Center for Biotechnology Information) database (www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=543) can be used. Examples of bacteria from the family *Enterobacteriaceae* that can be modified include a bacterium of the genus *Escherichia*, *Enterobacter*, or *Pantoea*.

[0039] *Escherichia* bacteria which can be modified to obtain *Escherichia* bacteria in accordance with the presently disclosed subject matter are not particularly limited, and specifically, those described in the work of Neidhardt et al. can be used (Bachmann, B.J., Derivations and genotypes of some mutant derivatives of *E. coli* K-12, p. 2460-2488. In F.C. Neidhardt et al. (ed.), *E. coli* and *Salmonella*: cellular and molecular biology, 2nd ed. ASM Press, Washington, D.C., 1996). The species *E. coli* is a particular example. Specific examples of *E. coli* include *E. coli* W3110 (ATCC 27325), *E. coli* MG1655 (ATCC 47076), and so forth, which are derived from the prototype wild-type strain, *E. coli* K-12 strain. These strains are available from, for example, the American Type Culture Collection (P.O. Box 1549, Manassas, VA 20108, United States of America). That is, registration numbers are given to each of the strains, and the strains can be ordered by using these registration numbers (refer to www.atcc.org). The registration numbers of the strains are listed in the catalogue of the American Type Culture Collection.

[0040] Examples of the *Enterobacter* bacteria include *Enterobacter agglomerans*, *Enterobacter aerogenes*, and so forth. Examples of the *Pantoea* bacteria include *Pantoea ananatis* (*P. ananatis*), and so forth. Some strains of *Enterobacter agglomerans* were recently reclassified into *Pantoea agglomerans*, *Pantoea ananatis*, or *Pantoea stewartii* on the basis of nucleotide sequence analysis of 16S rRNA, etc. A bacterium belonging to either genus *Enterobacter* or *Pantoea* may be used so long as it is a bacterium classified into the family *Enterobacteriaceae*. When a *P. ananatis* strain is bred by genetic engineering techniques, *P. ananatis* AJ13355 strain (FERM BP-6614), AJ13356 strain (FERM BP-6615), AJ13601 strain (FERM BP-7207), and derivatives thereof can be used. These strains were identified as *Enterobacter agglomerans* when they were isolated, and deposited as *Enterobacter agglomerans*. However, they were recently reclassified as *Pantoea ananatis* on the basis of nucleotide sequencing of 16S rRNA and so forth as described above.

[0041] Hereafter, L-amino acid-producing bacteria will be specifically exemplified. Any of the properties of the L-amino acid-producing bacteria and modifications for imparting or enhancing an L-amino acid-producing ability, such as those exemplified below, can be used independently or in any appropriate combination.

L-Arginine producing bacteria

[0042] Examples of L-arginine-producing bacteria and parental strains which can be used to derive L-arginine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* strain 237 (VKPM B-7925) (U.S. Patent Application No. 2002058315 A1) and its derivative strains harboring mutant N-acetylglutamate synthase (Russian Patent No. 2215783 C2), *E. coli* strain 382 (VKPM B-7926, EP1170358 A1), which is a strain derived from the strain 237 and having an improved acetic acid-assimilating ability, *E. coli* strain 382 *ilvA*⁺, which is a strain obtained from the strain 382 by introducing the wild-type allele of *ilvA* gene from *E. coli* K-12 strain thereto, and the like. Examples of mutant N-acetylglutamate synthase include, for example, a mutant N-acetylglutamate synthase desensitized to feedback inhibition by L-arginine by substitution for the amino acid residues corresponding to the positions 15 to 19 of the wild type enzyme (EP1170361 A1).

[0043] Examples of L-arginine-producing bacteria and parental strains which can be used to derive L-arginine-producing bacteria also include strains in which expression of one or more genes encoding an L-arginine biosynthetic enzyme are enhanced. Examples of such genes include genes encoding N-acetyl- γ -glutamylphosphate reductase (*argC*), ornithine acetyltransferase (*argJ*), N-acetylglutamate kinase (*argB*), N-acetylornithine aminotransferase (*argD*), ornithine carbamoyltransferase (*argF*), argininosuccinate synthase (*argG*), argininosuccinate lyase (*argH*), and carbamoyl phosphate synthetase (*carAB*), in addition to the gene encoding N-acetylglutamate synthase (*argA*).

[0044] Examples of L-arginine-producing bacteria and parental strains which can be used to derive L-arginine-producing bacteria also include strains having resistance to amino acid analogues, and so forth. Examples of such strains include *Escherichia coli* mutant strains having resistance to α -methylmethionine, p-fluorophenylalanine, D-arginine, arginine hydroxamate, S-(2-aminoethyl)-cysteine, α -methylserine, β -2-thienylalanine, or sulfaguanidine (refer to Japanese Patent Laid-open (Kokai) No. 56-106598).

L-Citrulline-producing bacteria

[0045] Examples of L-citrulline-producing bacteria and parental strains which can be used to derive L-citrulline-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* strains 237/pMADS11, 237/pMADS12, and 237/pMADS13 (RU2215783 C2, European Patent No. 1170361 B1, U.S. Patent No. 6,790,647 B2), which harbor mutant N-acetylglutamate synthase, *E. coli* strains 333 (VKPM B-8084) and 374 (VKPM B-8086), both harboring mutant feedback-resistant carbamoyl phosphate synthetase (Russian Patent No. 2264459 C2), *E. coli* strains in which α -ketoglutarate synthase activity is increased, and ferredoxin NADP⁺ reductase, pyruvate synthase, and/or α -ketoglutarate dehydrogenase activities are additionally modified (EP2133417 A1), and *P. ananatis* strain NA1sucAsdH_A, in which succinate dehydrogenase and α -ketoglutarate dehydrogenase activities are decreased (U.S. Patent Application No. 2009286290 A1), and the like.

[0046] As L-citrulline is an intermediate of L-arginine biosynthetic pathway, examples of L-citrulline-producing bacteria

and parent strains which can be used to derive L-citrulline-producing bacteria, include strains in which expression of one or more genes encoding an L-arginine biosynthetic enzyme is enhanced. Examples of such genes include, but are not limited to, genes encoding N-acetylglutamate synthase (*argA*), N-acetylglutamate kinase (*argB*), N-acetylglutamyl phosphate reductase (*argC*), acetylornithine transaminase (*argD*), acetylornithine deacetylase (*argE*), ornithine carbamoyltransferase (*argFII*), and carbamoyl phosphate synthetase (*carAB*), and combinations thereof.

[0047] An L-citrulline-producing bacterium can be also easily obtained from any L-arginine-producing bacterium, for example *E. coli* 382 strain (VKPM B-7926), by inactivation of argininosuccinate synthase encoded by *argG* gene.

L-Cysteine producing bacteria

[0048] Examples of L-cysteine-producing bacteria and parental strains which can be used to derive L-cysteine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* JM 15 transformed with different *cysE* alleles encoding feedback-resistant serine acetyltransferases (U.S. Patent No. 6,218,168 B1, Russian Patent No. 2279477 C2), *E. coli* W3110 having overexpressed genes which encode proteins suitable for secreting substances toxic for cells (U.S. Patent No. 5,972,663 A), *E. coli* strains having a lowered cysteine desulfhydrase activity (JP11155571 A2), *E. coli* W3110 having an increased activity of a positive transcriptional regulator for cysteine regulon encoded by the *cysB* gene (WO0127307 A1), and the like. Examples of L-cysteine-producing bacteria and parental strains which can be used to derive L-cysteine-producing bacteria also include *E. coli* strain JM15(ydeD), which is a derivative of *E. coli* JM15 (U.S. Patent No. 6,218,168 B1), and has been transformed with DNA containing the *ydeD* gene (U.S. Patent No. 5,972,663).

L-Glutamic acid-producing bacteria

[0049] Examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive L-glutamic acid-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* VL334thrC⁺ (EP 1172433 A1). The *E. coli* VL334 (VKPM B-1641) is an L-isoleucine and L-threonine auxotrophic strain having mutations in *thrC* and *ilvA* genes (U.S. Patent No. 4,278,765). A wild-type allele of the *thrC* gene was transferred by the method of general transduction using a bacteriophage P1 grown on the wild-type *E. coli* strain K-12 (VKPM B-7) cells. As a result, an L-isoleucine auxotrophic strain VL334thrC⁺ (VKPM B-8961), which is able to produce L-glutamic acid, was obtained.

[0050] Examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive the L-glutamic acid-producing bacteria include, but are not limited to, strains in which expression of one or more genes encoding an L-glutamic acid biosynthetic enzyme are enhanced. Examples of such genes include genes encoding glutamate dehydrogenase (*gdhA*), glutamine synthetase (*glnA*), glutamate synthetase (*gltBD*), isocitrate dehydrogenase (*icdA*), aconitate hydratase (*acnA*, *acnB*), citrate synthase (*gltA*), pyruvate carboxylase (*pyc*), pyruvate dehydrogenase (*aceEF*, *lpdA*), pyruvate kinase (*pykA*, *pykF*), phosphoenolpyruvate synthase (*ppsA*), enolase (*eno*), phosphoglyceromutase (*pgmA*, *pgmI*), phosphoglycerate kinase (*pgk*), glyceraldehyde-3-phosphate dehydrogenase (*gapA*), triose phosphate isomerase (*tpiA*), fructose bisphosphate aldolase (*fbp*), and glucose phosphate isomerase (*pgi*).

[0051] Examples of strains modified so that expression of the citrate synthetase gene, the phosphoenolpyruvate carboxylase gene, and/or the glutamate dehydrogenase gene is/are enhanced include those disclosed in EP1078989 A2, EP955368 A2, and EP952221 A2.

[0052] Examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive the L-glutamic acid-producing bacteria also include strains having a decreased or eliminated activity of an enzyme that catalyzes synthesis of a compound other than L-glutamic acid by branching off from an L-glutamic acid biosynthesis pathway. Examples of such enzymes include isocitrate lyase (*aceA*), α -ketoglutarate dehydrogenase (*sucA*), acetolactate synthase (*ilvI*), formate acetyltransferase (*pfl*), lactate dehydrogenase (*ldh*), glutamate decarboxylase (*gadAB*), and succinate dehydrogenase (*sdhABCD*). Shown in the parentheses after the names of the enzymes are examples of the genes encoding the enzymes (the same shall apply to the same occasions hereafter). Bacteria belonging to the genus *Escherichia* deficient in the α -ketoglutarate dehydrogenase activity or having a reduced α -ketoglutarate dehydrogenase activity and methods for obtaining them are described in U.S. Patent Nos. 5,378,616 and 5,573,945. Specifically, these strains include the following:

E. coli W3110sucA::Km^R,
E. coli AJ12624 (FERM BP-3853),
E. coli AJ12628 (FERM BP-3854),
E. coli AJ12949 (FERM BP-4881).

[0053] *E. coli* W3110sucA::Km^R is a strain obtained by disrupting the α -ketoglutarate dehydrogenase gene (hereinafter

referred to as "sucA gene") of *E. coli* W3110. This strain is completely deficient in the α -ketoglutarate dehydrogenase.

[0054] Other examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive the L-glutamic acid-producing bacteria include strains that belong to the genus *Escherichia* and have resistance to an aspartic acid antimetabolite (aspartic acid analogue). These strains can also be deficient in the α -ketoglutarate dehydrogenase activity and examples thereof include, for example, *E. coli* AJ13199 (FERM BP-5807) (U.S. Patent No. 5,908,768), *E. coli* FFRM P-12379, which additionally has a lowered L-glutamic acid-decomposing ability (U.S. Patent No. 5,393,671), *E. coli* AJ13138 (FERM BP-5565) (U.S. Patent No. 6,110,714), and the like.

[0055] Examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive the L-glutamic acid-producing bacteria also include *Pantoea* bacteria, such as the *P. ananatis* AJ13355 strain (FERM BP-6614), *P. ananatis* SC17 strain (FERM BP-11091), and *P. ananatis* SC17(0) strain (VKPM B-9246). The AJ13355 strain is a strain isolated from soil in Iwata-shi, Shizuoka-ken, Japan as a strain that can proliferate in a low pH medium containing L-glutamic acid and a carbon source. The SC17 strain is a strain selected as a low phlegm-producing mutant strain from the AJ13355 strain (U.S. Patent No. 6,596,517). The SC17 strain was deposited at the independent administrative agency, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depository (currently, independent administrative agency, National Institute of Technology and Evaluation, International Patent Organism Depository (NITE IPOD), #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on February 4, 2009, and assigned an accession number of FERM BP-11091. The AJ13355 strain was deposited at the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, NITE IPOD, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on February 19, 1998 and assigned an accession number of FERM P-16644. Then, the deposit was converted to an international deposit under the provisions of the Budapest Treaty on January 11, 1999, and assigned an accession number of FERM BP-6614.

[0056] Examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive the L-glutamic acid-producing bacteria also include mutant strains belonging to the genus *Pantoea* that are deficient in the α -ketoglutarate dehydrogenase activity or have a decreased α -ketoglutarate dehydrogenase activity, and can be obtained as described above. Such strains include *P. ananatis* AJ13356 (U.S. Patent No. 6,331,419 B1). *P. ananatis* AJ13356 was deposited at the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, NITE IPOD, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on February 19, 1998 under the accession number FERM P-16645. It was then converted to an international deposit under the provisions of the Budapest Treaty on January 11, 1999 and received an accession number of FERM BP-6615. *P. ananatis* AJ13356 is deficient in α -ketoglutarate dehydrogenase activity as a result of disruption of the α KGDH-E1 subunit gene (*sucA*). The above strain was identified as *Enterobacter agglomerans* when it was isolated and deposited as the *Enterobacter agglomerans* AJ13356. However, it was recently re-classified as *Pantoea ananatis* on the basis of nucleotide sequencing of 16S rRNA and so forth. Although AJ13356 was deposited at the aforementioned depository as *Enterobacter agglomerans*, for the purposes of this specification, they are described as *P. ananatis*.

[0057] Examples of L-glutamic acid-producing bacteria and parental strains which can be used to derive the L-glutamic acid-producing bacteria also include strains belonging to the genus *Pantoea* such as the *P. ananatis* SC17sucA/RS-FCPG+pSTVCB strain, *P. ananatis* AJ13601 strain, *P. ananatis* NP106 strain, and *P. ananatis* NA1 strain. The SC17sucA/RSFCPG+pSTVCB strain was obtained by introducing the plasmid RSFCPG containing the citrate synthase gene (*gltA*), phosphoenolpyruvate carboxylase gene (*ppc*), and glutamate dehydrogenase gene (*gdhA*) derived from *Escherichia coli*, and the plasmid pSTVCB containing the citrate synthase gene (*gltA*) derived from *Brevibacterium lactofermentum*, into the SC17sucA strain. The AJ13601 strain is a strain selected from the SC17sucA/RS-FCPG+pSTVCB strain as a strain resistant to a high concentration of L-glutamic acid at a low pH. The NP106 strain was obtained from the AJ13601 strain by curing the RSFCPG and pSTVCB plasmids. The AJ13601 strain was deposited at the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently, NITE IPOD, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on August 18, 1999, and assigned an accession number FERM P-17516. Then, the deposit was converted to an international deposit under the provisions of the Budapest Treaty on July 6, 2000, and assigned an accession number FERM BP-7207.

L-Histidine-producing bacteria

[0058] Examples of L-histidine-producing bacteria and parental strains which can be used to derive L-histidine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* strain 24 (VKPM B-5945, RU2003677 C1), *E. coli* strain 80 (VKPM B-7270, RU2119536 C1), *E. coli* NRRL B-12116 - B-12121 (U.S. Patent No. 4,388,405), *E. coli* H-9342 (FERM BP-6675) and H-9343 (FERM BP-6676) (U.S. Patent No. 6,344,347 B1), *E. coli* H-9341 (FERM BP-6674) (EP1085087 A2), *E. coli* AI80/pFM201 (U.S. Patent No. 6,258,554 B1), and the like.

[0059] Examples of L-histidine-producing bacteria and parental strains which can be used to derive L-histidine-producing bacteria also include strains in which expression of one or more genes encoding an L-histidine biosynthetic enzyme are enhanced. Examples of such genes include genes encoding ATP phosphoribosyltransferase (*hisG*), phosphoribosyl-AMP cyclohydrolase (*hisI*), phosphoribosyl-AMP cyclohydrolase/phosphoribosyl-ATP pyrophosphatase (*hisE*), phosphoribosylformimino-5-aminoimidazole carboxamide ribotide isomerase (*hisA*), amidotransferase (*hisH*), histidinol phosphate aminotransferase (*hisC*), histidinol phosphatase (*hisB*), histidinol dehydrogenase (*hisD*), and so forth.

[0060] It is known that the L-histidine biosynthetic enzymes encoded by *hisG* and *hisBHAFI* are inhibited by L-histidine, and therefore an L-histidine-producing ability can also be efficiently enhanced by introducing a mutation conferring resistance to the feedback inhibition into ATP phosphoribosyltransferase (Russian Patent Nos. 2003677 C1 and 2119536 C1).

[0061] Specific examples of strains having an L-histidine-producing ability include *E. coli* FERM-P 5038 and 5048, which have been transformed with a vector carrying a DNA encoding an L-histidine-biosynthetic enzyme (JP 56-005099 A), *E. coli* strains transformed with *rht*, a gene for an amino acid-export (EP1016710 A2), *E. coli* 80 strain, which has been imparted with sulfaguanidine, DL-1,2,4-triazole-3-alanine, and streptomycin-resistance (VKPM B-7270, RU2119536 C1), *E. coli* MG1655+*hisGr hisL' Δ ΔpurR* (RU2119536 and Doroshenko V.G. et al., The directed modification of *Escherichia coli* MG1655 to obtain histidine-producing mutants, Prikl. Biochim. Mikrobiol. (Russian), 2013, 49(2):149-154), and so forth.

L-Isoleucine producing bacteria

[0062] Examples of L-isoleucine-producing bacteria and parental strains which can be used to derive L-isoleucine-producing bacteria include, but are not limited to, mutant strains having resistance to 6-dimethylaminopurine (JP 5-304969 A), mutant strains having resistance to an isoleucine analogue such as thiaisoleucine and isoleucine hydroxamate, and mutant strains additionally having resistance to DL-ethionine and/or arginine hydroxamate (JP 5-130882 A). In addition, recombinant strains transformed with genes encoding proteins involved in L-isoleucine biosynthesis, such as threonine deaminase and acetohydroxate synthase, can also be used as L-isoleucine-producing bacteria or parental strains thereof (JP 2-458 A, EP0356739 A1, and U.S. Patent No. 5,998,178).

L-Leucine-producing bacteria

[0063] Examples of L-leucine-producing bacteria and parental strains which can be used to derive L-leucine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* strains resistant to leucine (for example, the strain 57 (VKPM B-7386, U.S. Patent No. 6,124,121)); *E. coli* strains resistant to leucine analogs including β-2-thienylalanine, 3-hydroxyleucine, 4-azaleucine, 5,5,5-trifluoroleucine (JP 62-34397 B and JP 8-70879 A); *E. coli* strains obtained by the gene engineering method described in WO96/06926; *E. coli* H-9068 (JP 8-70879 A), and the like.

[0064] Examples of L-leucine-producing bacteria and parental strains which can be used to derive L-leucine-producing bacteria also include strains in which the expression of one or more genes involved in L-leucine biosynthesis is enhanced. Examples of such genes include genes of the *leuABCD* operon, which can be represented by a mutant *leuA* gene encoding α-isopropylmalate synthase freed from feedback inhibition by L-leucine (U.S. Patent No. 6,403,342 B1). In addition, examples of L-leucine-producing bacteria and parental strains which can be used to derive L-leucine-producing bacteria also include strains in which the expression of one or more genes encoding proteins which excrete L-amino acid from the bacterial cell is enhanced. Examples of such genes include the *b2682* and *b2683* genes (*ygaZH* genes) (EP1239041 A2).

L-Lysine-producing bacteria

[0065] Examples of L-lysine-producing bacteria and parental strains which can be used to derive L-lysine-producing bacteria include mutant strains belonging to the genus *Escherichia* and having resistance to an L-lysine analogue. The L-lysine analogue inhibits growth of bacteria belonging to the genus *Escherichia*, but this inhibition is fully or partially desensitized when L-lysine is present in the medium. Examples of the L-lysine analogue include, but are not limited to, oxalysine, lysine hydroxamate, S-(2-aminoethyl)-L-cysteine (AEC), γ-methyllysine, α-chlorocaprolactam, and so forth. Mutant strains having resistance to these lysine analogues can be obtained by subjecting bacteria belonging to the genus *Escherichia* to a conventional artificial mutagenesis treatment. Specific examples of bacterial strains useful for producing L-lysine include *E. coli* AJ11442 (FERM BP-1543, NRRL B-12185; see U.S. Patent No. 4,346,170) and *E. coli* VL611. In these strains, feedback inhibition of aspartokinase by L-lysine is desensitized.

[0066] Examples of L-lysine-producing bacteria and parental strains which can be used to derive L-lysine-producing

bacteria also include strains in which expression of one or more genes encoding an L-lysine biosynthetic enzyme is enhanced. Examples of such genes include, but are not limited to, genes encoding dihydrodipicolinate synthase (*dapA*), aspartokinase III (*lysC*), dihydrodipicolinate reductase (*dapB*), diaminopimelate decarboxylase (*lysA*), diaminopimelate dehydrogenase (*ddh*) (U.S. Patent No. 6,040,160), phosphoenolpyruvate carboxylase (*ppc*), aspartate semialdehyde dehydrogenase (*asd*), and aspartase (*aspA*) (EP1253195 A1). In addition, the L-lysine-producing bacteria or parental strains thereof may have an increased level of expression of the gene involved in energy efficiency (*cyo*) (EP1170376 A1), the gene encoding nicotinamide nucleotide transhydrogenase (*pntAB*) (U.S. Patent No. 5,830,716 A), the *ybjE* gene (WO2005/073390), or combinations thereof. Since aspartokinase III is subject to feedback inhibition by L-lysine, a mutant *lysC* gene coding for an aspartokinase III desensitized to feedback inhibition by L-lysine (U.S. Patent No. 5,932,453) may be used for enhancing the activity of this enzyme. Further, since dihydrodipicolinate synthase is subject to feedback inhibition by L-lysine, a mutant *dapA* gene coding for a dihydrodipicolinate synthase desensitized to feedback inhibition by L-lysine may be used for enhancing the activity of this enzyme.

[0067] L-Lysine-producing bacteria or parental strains which can be used to derive L-lysine-producing bacteria may have a reduced or no activity of an enzyme that catalyzes a reaction which causes a branching off from the L-lysine biosynthesis pathway and results in the production of another compound. Also, L-lysine-producing bacteria or parental strains which can be used to derive L-lysine-producing bacteria may have a reduced or no activity of an enzyme that negatively acts on L-lysine synthesis or accumulation. Examples of such enzymes involved in L-lysine production include homoserine dehydrogenase, lysine decarboxylase (*cadA*, *ldcC*), malic enzyme, and so forth, and strains in which activities of these enzymes are decreased or deleted are disclosed in WO95/23864, WO96/17930, WO2005/010175, and so forth.

[0068] Expression of both the *cadA* and *ldcC* genes encoding lysine decarboxylase can be decreased in order to decrease or delete the lysine decarboxylase activity. Expression of the both genes can be decreased by, for example, the method described in WO2006/078039.

[0069] Examples of L-lysine-producing bacteria and parental strains which can be used to derive L-lysine-producing bacteria also include the *E. coli* WC196 strain (U.S. Patent No. 5,827,698), the *E. coli* WC196 Δ *cadA* Δ *ldcC* strain, and the *E. coli* WC196 Δ *cadA* Δ *ldcC*/pCABD2 strain (WO2006/078039).

[0070] The WC 196 strain was bred from the W3110 strain, which was derived from *E. coli* K-12, by conferring AEC resistance to the W3110 strain (U.S. Patent No. 5,827,698). The WC196 strain was designated *E. coli* AJ13069, deposited at the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (currently, NITE IPOD, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on December 6, 1994, and assigned an accession number of FERM P-14690. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on September 29, 1995, and assigned an accession number of FERM BP-5252 (U.S. Patent No. 5,827,698).

[0071] The WC196 Δ *cadA* Δ *ldcC* strain was constructed from the WC196 strain by disrupting the *cadA* and *ldcC* genes which encode lysine decarboxylase. The WC196 Δ *cadA* Δ *ldcC* was designated AJ110692 and deposited at the independent administrative agency, National Institute of Advanced Industrial Science and Technology, International Patent Organism Depository (currently, NITE IPOD, #120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on October 7, 2008 as an international deposit under the accession number FERM BP-11027.

[0072] The WC196 Δ *cadA* Δ *ldcC*/pCABD2 strain was constructed by introducing the plasmid pCABD2 containing lysine biosynthesis genes (U.S. Patent No. 6,040,160) into the WC196 Δ *cadA* Δ *ldcC* strain. The plasmid pCABD2 contains a mutant *dapA* gene derived from *Escherichia coli* and coding for a dihydrodipicolinate synthase (DDPS) having a mutation for desensitization to feedback inhibition by L-lysine (H118Y), a mutant *lysC* gene derived from *Escherichia coli* and coding for aspartokinase III having a mutation for desensitization to feedback inhibition by L-lysine (T352I), the *dapB* gene derived from *Escherichia coli* and coding for dihydrodipicolinate reductase, and the *ddh* gene derived from *Brevibacterium lactofermentum* and coding for diaminopimelate dehydrogenase.

[0073] Examples of L-lysine-producing bacteria and parental strains which can be used to derive L-lysine-producing bacteria also include *E. coli* AJIKO1 (NITE BP-01520). The AJIKO1 strain was designated *E. coli* AJ111046, and deposited at NITE IPOD (#120, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba-ken, 292-0818, Japan) on January 29, 2013. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on May 15, 2014, and assigned an accession number of NITE BP-01520.

L-Methionine-producing bacteria

[0074] Examples of L-methionine-producing bacteria and parent strains which can be used to derive L-methionine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* strains AJ11539 (NRRL B-12399), AJ11540 (NRRL B-12400), AJ11541 (NRRL B-12401), AJ 11542 (NRRL B-12402) (Patent GB2075055); and *E. coli* strains 218 (VKPM B-8125) (RU2209248 C2) and 73 (VKPM B-8126) (RU2215782 C2) resistant to norleucine, the L-methionine analog, or the like. The strain *E. coli* 73 was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny

proezd, 1) on May 14, 2001 under the accession number VKPM B-8126. Then, it was converted to an international deposit under the provisions of the Budapest Treaty on February 1, 2002. Furthermore, a methionine repressor-deficient strain and recombinant strains transformed with genes encoding proteins involved in L-methionine biosynthesis such as homoserine transsuccinylase and cystathionine γ -synthase (JP 2000-139471 A) can also be used as L-methionine-producing bacteria or parent strains thereof.

L-Ornithine-producing bacteria

[0075] As L-ornithine is an intermediate of L-arginine biosynthetic pathway, examples of L-ornithine-producing bacteria and parent strains which can be used to derive L-ornithine-producing bacteria, include strains in which expression of one or more genes encoding an L-arginine biosynthetic enzyme, such as those described above, is enhanced.

[0076] An L-ornithine-producing bacterium can be easily obtained from any L-arginine-producing bacterium, for example *E. coli* 382 strain (VKPM B-7926), by inactivation of ornithine carbamoyltransferase encoded by both *argF* and *argI* genes. Methods for inactivation of ornithine carbamoyltransferase are described herein.

L-Phenylalanine-producing bacteria

[0077] Examples of L-phenylalanine-producing bacteria and parental strains which can be used to derive L-phenylalanine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* AJ12739 (*tyrA::Tn10, tyrR*) (VKPM B-8197), *E. coli* HW1089 (ATCC 55371) harboring the mutant *pheA34* gene (U.S. Patent No. 5,354,672), *E. coli* MVEC101-b (KR8903681), *E. coli* NRRL B-12141, NRRL B-12145, NRRL B-12146, and NRRL B-12147 (U.S. Patent No. 4,407,952), *E. coli* K-12 [W3110 (*tyrA*)/pPHAB] (FERM BP-3566), *E. coli* K-12 [W3110 (*tyrA*)/pPHAD] (FERM BP-12659), *E. coli* K-12 [W3110 (*tyrA*)/pPHATerm] (FERM BP-12662), and *E. coli* K-12 [W3110 (*tyrA*)/pBR-aroG4, pACMAB] named as AJ12604 (FERM BP-3579) (EP488424 B1). Furthermore, L-phenylalanine-producing bacteria and parental strains which can be used to derive L-phenylalanine-producing bacteria also include strains belonging to the genus *Escherichia* and having an enhanced activity of the protein encoded by the *yedA* gene or the *yddG* gene (U.S. Patent Nos. 7,259,003 and 7,666,655).

L-Proline-producing bacteria

[0078] Examples of L-proline-producing bacteria and parental strains which can be used to derive L-proline-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* 702ilvA (VKPM B-8012), which is deficient in the *ilvA* gene and is able to produce L-proline (EP1172433 A1). Examples of L-proline-producing bacteria and parental strains which can be used to derive L-proline-producing bacteria also include strains in which the expression of one or more genes involved in L-proline biosynthesis is enhanced. Examples of such genes which can be used in L-proline-producing bacteria include the *proB* gene encoding glutamate kinase with desensitized feedback inhibition by L-proline (DE3127361 A1). In addition, examples of L-proline-producing bacteria and parental strains which can be used to derive L-proline-producing bacteria also include strains in which the expression of one or more genes encoding proteins responsible for excreting L-amino acid from the bacterial cell is enhanced. Examples of such genes include the *b2682* and *b2683* genes (*ygaZH* genes) (EP1239041 A2).

[0079] Examples of bacteria belonging to the genus *Escherichia* that have an ability to produce L-proline include the following *E. coli* strains: NRRL B-12403 and NRRL B-12404 (GB Patent 2075056), VKPM B-8012 (Russian Patent No. 2207371 C2), plasmid mutants described in DE3127361 A1, plasmid mutants described by Bloom F.R. et al. in "The 15th Miami winter symposium", 1983, p.34, and the like.

L-Threonine-producing bacteria

[0080] Examples of L-threonine-producing bacteria and parental strains which can be used to derive L-threonine-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* TDH-6/pVIC40 (VKPM B-3996) (U.S. Patent Nos. 5,175,107 and 5,705,371), *E. coli* 472T23/pYN7 (ATCC 98081) (U.S. Patent No. 5,631,157), *E. coli* NRRL B-21593 (U.S. Patent No. 5,939,307), *E. coli* FERM BP-3756 (U.S. Patent No. 5,474,918), *E. coli* FERM BP-3519 and FERM BP-3520 (U.S. Patent No. 5,376,538), *E. coli* MG442 (Gusyatiner M. et al., Genetika (Russian), 1978, 14:947-956), *E. coli* VL643 and VL2055 (EP1149911 A2), *E. coli* VKPM B-5318 (EP0593792 A1), and the like.

[0081] The strain TDH-6 is deficient in the *thrC* gene, as well as being sucrose-assimilative, and the *ilvA* gene thereof has a leaky mutation. This strain also has a mutation in the *rhtA* gene, which mutation imparts resistance to high concentrations of threonine or homoserine. The strain VKPM B-3996, which contains the plasmid pVIC40, was obtained by introducing the plasmid pVIC40 into the TDH-6 strain. The plasmid pVIC40 was obtained by inserting a *thrA*BC*

operon which includes a mutant *thrA* gene into a RSF1010-derived vector. This mutant *thrA* gene encodes aspartokinase homoserine dehydrogenase I which has substantially desensitized feedback inhibition by threonine. The strain VKPM B-3996 was deposited on November 19, 1987 in the All-Union Scientific Center of Antibiotics (Russian Federation, 117105 Moscow, Nagatinskaya Street 3-A) under the accession number RIA 1867. The strain VKPM B-3996 was also

deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on April 7, 1987 under the accession number VKPM B-3996. [0082] The strain B-5318 is prototrophic with regard to isoleucine; and harbors the plasmid pPRT614, which corresponds to the plasmid pVIC40 of which the regulatory region of the threonine operon is replaced with a temperature-sensitive lambda-phage C1 repressor and PR promoter. The strain VKPM B-5318 was deposited in the Russian National

Collection of Industrial Microorganisms (VKPM) on May 3, 1990 under the accession number VKPM B-5318. [0083] L-Threonine-producing bacteria or parental strains which can be used to derive L-threonine-producing bacteria can be modified to enhance expression of one or more of the following genes:

- the mutant *thrA* gene which encodes aspartokinase homoserine dehydrogenase I resistant to feedback inhibition by threonine;
- the *thrB* gene which encodes homoserine kinase;
- the *thrC* gene which encodes threonine synthase;
- the *rhtA* gene which encodes a putative transmembrane protein of the threonine and homoserine efflux system;
- the *asd* gene which encodes aspartate- β -semialdehyde dehydrogenase; and
- the *aspC* gene which encodes aspartate aminotransferase (aspartate transaminase);

[0084] The *thrA* gene which encodes aspartokinase I and homoserine dehydrogenase I of *E. coli* has been elucidated (KEGG, Kyoto Encyclopedia of Genes and Genomes, entry No. b0002; GenBank, accession No. NC_000913.2; nucleotide positions: 337 to 2,799; Gene ID: 945803). The *thrA* gene is located between the *thrL* and *thrB* genes on the

chromosome of *E. coli* K-12. [0085] The *thrB* gene which encodes homoserine kinase of *E. coli* has been elucidated (KEGG, entry No. b0003; GenBank, accession No. NC_000913.2; nucleotide positions: 2,801 to 3,733; Gene ID: 947498). The *thrB* gene is located between the *thrA* and *thrC* genes on the chromosome of *E. coli* K-12.

[0086] The *thrC* gene which encodes threonine synthase of *E. coli* has been elucidated (KEGG, entry No. b0004; GenBank, accession No. NC_000913.2; nucleotide positions: 3,734 to 5,020; Gene ID: 945198). The *thrC* gene is located between the *thrB* and *yaaX* genes on the chromosome of *E. coli* K-12. All three genes function as a single threonine operon *thrABC*. To enhance expression of the threonine operon, the attenuator region which affects the transcription is desirably removed from the operon (WO2005049808 A1, WO2003097839 A1).

[0087] The mutant *thrA* gene which encodes aspartokinase I and homoserine dehydrogenase I resistant to feedback inhibition by L-threonine, as well as, the *thrB* and *thrC* genes can be obtained as one operon from the well-known plasmid pVIC40 which is present in the L-threonine-producing *E. coli* strain VKPM B-3996. Plasmid pVIC40 is described in detail in U.S. Patent No. 5,705,371.

[0088] The *rhtA* gene which encodes a protein of the threonine and homoserine efflux system (an inner membrane transporter) of *E. coli* has been elucidated (KEGG, entry No. b0813; GenBank, accession No. NC_000913.2; nucleotide positions: 848,433 to 849,320, complement; Gene ID: 947045). The *rhtA* gene is located between the *dps* and *ompX* genes on the chromosome of *E. coli* K-12 close to the *glnHPQ* operon, which encodes components of the glutamine transport system. The *rhtA* gene is identical to the *ybiF* gene (KEGG, entry No. b0813).

[0089] The *asd* gene which encodes aspartate- β -semialdehyde dehydrogenase of *E. coli* has been elucidated (KEGG, entry No. b3433; GenBank, accession No. NC_000913.2; nucleotide positions: 3,571,798 to 3,572,901, complement; Gene ID: 947939). The *asd* gene is located between the *glgB* and *gntU* gene on the same strand (*yhgN* gene on the opposite strand) on the chromosome of *E. coli* K-12.

[0090] Also, the *aspC* gene which encodes aspartate aminotransferase of *E. coli* has been elucidated (KEGG, entry No. b0928; GenBank, accession No. NC_000913.2; nucleotide positions: 983,742 to 984,932, complement; Gene ID: 945553). The *aspC* gene is located between the *ycbL* gene on the opposite strand and the *ompF* gene on the same strand on the chromosome of *E. coli* K-12.

L-Tryptophan-producing bacteria

[0091] Examples of L-tryptophan-producing bacteria and parental strains which can be used to derive the L-tryptophan-producing bacteria include, but are not limited to, strains belonging to the genus *Escherichia* such as *E. coli* JP4735/pMU3028 (DSM10122) and JP6015/pMU91 (DSM10123), which have a mutant *trpS* gene encoding a partially inactivated tryptophanyl-tRNA synthetase (U.S. Patent No. 5,756,345), *E. coli* SV164 (pGH5) having a *serA* allele encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine and a *trpE* allele encoding anthranilate

synthase free from feedback inhibition by tryptophan (U.S. Patent No. 6,180,373 B1), *E. coli* AGX17 (pGX44) (NRRL B-12263) and AGX6(pGX50)aroP (NRRL B-12264) deficient in the enzyme tryptophanase (U.S. Patent No. 4,371,614), *E. coli* AGX17/pGX50,pACKG4-pps having an enhanced phosphoenolpyruvate-producing ability (WO97/08333, U.S. Patent No. 6,319,696 B1), and the like. Examples of L-tryptophan-producing bacteria and parental strains which can be used to derive the L-tryptophan-producing bacteria also include strains belonging to the genus *Escherichia* and having an enhanced activity of the protein encoded by and the *yedA* gene or the *yddG* gene (U.S. Patent Application Nos. 2003148473 A1 and 2003157667 A1).

[0092] Examples of L-tryptophan-producing bacteria and parental strains which can be used to derive the L-tryptophan-producing bacteria also include strains in which one or more activities of the enzymes selected from anthranilate synthase, phosphoglycerate dehydrogenase, and tryptophan synthase are enhanced. The anthranilate synthase and phosphoglycerate dehydrogenase are both subject to feedback inhibition by L-tryptophan and L-serine, and hence, a mutation desensitizing the feedback inhibition may be introduced into these enzymes. Specific examples of strains having such a mutation include *E. coli* SV164, which harbors desensitized anthranilate synthase, and a transformant strain obtained by introducing into the *E. coli* SV164 the plasmid pGH5 (WO94/08031 A1), which contains a mutant *serA* gene encoding feedback-desensitized phosphoglycerate dehydrogenase.

[0093] Examples of L-tryptophan-producing bacteria and parental strains which can be used to derive the L-tryptophan-producing bacteria also include strains into which the tryptophan operon which contains a gene encoding desensitized anthranilate synthase has been introduced (JP 57-71397 A, JP 62-244382 A, U.S. Patent No. 4,371,614). Moreover, L-tryptophan-producing ability may be imparted by enhancing expression of a gene which encodes tryptophan synthase, among tryptophan operons (*trpBA*). The tryptophan synthase consists of α and β subunits which are encoded by the *trpA* and *trpB* genes, respectively. In addition, L-tryptophan-producing ability may be improved by enhancing expression of the isocitrate lyase-malate synthase operon (WO2005/103275).

L-Valine-producing bacteria

[0094] Examples of L-valine-producing bacteria and parental strains which can be used to derive L-valine-producing bacteria include, but are not limited to, strains which have been modified to overexpress the *ilvGMEDA* operon (U.S. Patent No. 5,998,178). It is desirable to remove the region of the *ilvGMEDA* operon which is required for attenuation so that expression of the operon is not attenuated by the L-valine that is produced. Furthermore, the *ilvA* gene in the operon is desirably disrupted so that threonine deaminase activity is decreased.

[0095] Examples of L-valine-producing bacteria and parental strains for deriving L-valine-producing bacteria also include mutant strains having a mutation in aminoacyl-tRNA synthetase (U.S. Patent No. 5,658,766). Examples of such strains include *E. coli* VL1970, which has a mutation in the *ileS* gene encoding isoleucine tRNA synthetase. *E. coli* VL1970 was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on June 24, 1988 under the accession number VKPM B-4411.

[0096] Furthermore, mutant strains requiring lipoic acid for growth and/or lacking H⁺-ATPase can also be used as L-valine-producing bacteria or parental strains thereof (WO96/06926 A1).

[0097] Examples of L-valine-producing bacteria and parent strains for deriving L-valine-producing bacteria also include *E. coli* H81 strain (VKPM B-8066; see, for example, EP1942183 B1), *E. coli* NRRL B-12287 and NRRL B-12288 (U.S. Patent No. 4,391,907), *E. coli* VKPM B-4411 (U.S. Patent No. 5,658,766), *E. coli* VKPM B-7707 (EP1016710 A2), or the like.

[0098] The bacterium of the present invention belonging to the family *Enterobacteriaceae* has been modified to attenuate expression of the *gshA* gene.

[0099] The phrase "*gshA* gene" can mean a gene which encodes an enzyme having an activity of γ -glutamate-cysteine ligase. A specific example of the gene which encodes the enzyme having the activity of γ -glutamate-cysteine ligase includes the *gshA* gene which encodes γ -glutamate-cysteine ligase. That is, the gene encoding the enzyme having the activity of γ -glutamate-cysteine ligase can be the *gshA* gene. The more specific description of *gshA* gene is given hereinafter.

[0100] The *gshA* gene (synonym: *gsh-I*) encodes γ -glutamate-cysteine ligase GshA (synonym: γ -glutamylcysteine synthetase, γ GCS) (KEGG, Kyoto Encyclopedia of Genes and Genomes, entry No. b2688; Protein Knowledgebase, UniProtKB/Swiss-Prot, accession No. POA6W9). The *gshA* gene (GenBank, accession No. NC_000913.3; nucleotide positions: 2814883 to 2816439, complement; Gene ID: 944881) is located between the *yqaA* gene on the same strand and the *micA* gene on the opposite strand on the chromosome of *E. coli* strain K-12. The nucleotide sequence of the *gshA* gene (SEQ ID NO: 1) of *E. coli* strain K-12 and the amino acid sequence of the γ GCS protein (SEQ ID NO: 2) encoded by the *gshA* gene of *E. coli* strain K-12 are known. That is, the *gshA* gene may have the nucleotide sequence of SEQ ID NO: 1, and the γ GCS protein encoded by the *gshA* gene may have the amino acid sequence of SEQ ID NO: 2. The phrase "a gene or protein has a nucleotide or amino acid sequence" encompasses cases where a gene or protein

comprises the nucleotide or amino acid sequence, and cases where a gene or protein consists of the nucleotide or amino acid sequence.

[0101] The phrase "a bacterium has been modified to attenuate expression of the *gshA* gene" can mean that the bacterium has been modified in such a way that in the modified bacterium expression of the *gshA* gene is attenuated. The phrase "a bacterium has been modified to attenuate expression of the *gshA* gene" can specifically mean that the bacterium has been modified in such a way that in the modified bacterium expression of the *gshA* gene is attenuated as compared with a non-modified bacterium. Exemplary, the expression of the *gshA* gene can be attenuated due to inactivation of the *gshA* gene.

[0102] The phrase "the *gshA* gene is inactivated" can mean that the modified gene encodes a completely inactive or non-functional protein, i.e. completely inactive or non-functional γ -glutamate-cysteine ligase. It is also acceptable that the modified DNA region is unable to naturally express the gene due to deletion of a part of the gene or deletion of the entire gene, replacement of one base or more to cause an amino acid substitution in the protein encoded by the gene (missense mutation), introduction of a stop codon (nonsense mutation), deletion of one or two bases to cause a reading frame shift of the gene, insertion of a drug-resistance gene and/or transcription termination signal, or modification of an adjacent region of the gene, including sequences controlling gene expression such as promoter(s), enhancer(s), attenuator(s), ribosome-binding site(s), etc. Inactivation of the gene can also be performed, for example, by conventional methods such as a mutagenesis treatment using UV irradiation or nitrosoguanidine (N-methyl-N'-nitro-N-nitrosoguanidine), site-directed mutagenesis, gene disruption using homologous recombination, and/or insertion-deletion mutagenesis (Yu D. et al., Proc. Natl. Acad. Sci. USA, 2000, 97(11):5978-5983; Datsenko K.A. and Wanner B.L., Proc. Natl. Acad. Sci. USA, 2000, 97(12):6640-6645; Zhang Y. et al., Nature Genet., 1998, 20:123-128) based on "Red/ET-driven integration" or " λ Red/ET-mediated integration".

[0103] The phrase "expression of the *gshA* gene is attenuated" can also mean that the modified bacterium contains a region operably linked to the *gshA* gene, including sequences controlling gene expression such as promoters, enhancers, attenuators and transcription termination signals, ribosome-binding sites, and other expression control elements, which is modified resulting in the decrease of the expression level of the *gshA* gene; and other examples (see, for example, WO95/34672; Carrier T.A. and Keasling J.D., Biotechnol. Prog., 1999, 15:58-64). The phrase "operably linked to the gene" can mean that the regulatory region(s) is/are linked to the nucleotide sequence of the nucleic acid molecule or gene in such a manner which allows for expression (e.g., enhanced, increased, constitutive, basal, antiterminated, attenuated, deregulated, decreased, or repressed expression) of the nucleotide sequence, specifically, the expression of a gene product encoded by the nucleotide sequence.

[0104] The phrase "expression of the *gshA* gene is attenuated" can also mean that the amount of the expression product of the *gshA* gene, such as the amount of mRNA of the gene or the amount of the γ GCS protein encoded by the gene, in the modified bacterium, in which expression of the *gshA* gene is attenuated, is reduced to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that in a non-modified bacterium.

[0105] The phrase "a bacterium has been modified to attenuate expression of the *gshA* gene" can also mean that the bacterium has been modified in such a way that in the modified bacterium the total enzymatic activity of the *gshA* gene product such as γ GCS protein is decreased as compared with a non-modified bacterium. The bacterium can be modified so that the activity of the γ GCS protein per cell is decreased to, for example, 50% or less, 20% or less, 10% or less, 5% or less, or 0% of that in a non-modified bacterium.

[0106] Examples of a non-modified bacterium serving as a reference for the above comparisons can include wild-type strains of a bacterium belonging to the genus *Escherichia*, such as the *E. coli* MG1655 strain (ATCC 47076) and *E. coli* W3110 strain (ATCC 27325), or a bacterium belonging to the genus *Pantoea*, such as the *P. ananatis* AJ13355 strain (FERM BP-6614), and so forth. Examples of a non-modified bacterium serving as a reference for the above comparisons can also include a parental strain which has not been modified to attenuate expression of the *gshA* gene or a bacterium in which expression of the *gshA* gene is not attenuated.

[0107] The phrase "activity of γ -glutamate-cysteine ligase" can mean the enzymatic activity of catalyzing the following reaction (EC number: 6.3.2.2): L-cysteine + L-glutamate + ATP \leftrightarrow γ -L-glutamyl-L-cysteine + ADP + phosphate + H⁺, where ATP can mean adenosine triphosphate and ADP can mean adenosine diphosphate.

[0108] The enzymatic activity of γ -glutamate-cysteine ligase can be determined by evaluating adenosine diphosphate (ADP) formation using a pyruvate kinase-lactate dehydrogenase-coupled assay (Seelig G.F. and Meister A., Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney, Methods Enzymol., 1985; 113:379-390) or dipeptide formation using L- α -[¹⁴C]aminobutyrate (Griffith O.W. and Meister A., Selective inhibition of gamma-glutamyl-cycle enzymes by substrate analogs, Proc. Natl. Acad. Sci. USA, 1977, 74(8):3330-3334). The direct measuring of γ -glutamyl-cysteine by high-performance liquid chromatography and electrochemical detection may also be used (Gegg M.E. et al., Determination of glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) activity by high-performance liquid chromatography and electrochemical detection, Anal. Biochem., 2002, 304(1):26-32). The protein concentration can be determined by the Bradford protein assay using bovine serum albumin as a standard (Bradford M.M., Anal. Biochem., 1976, 72:248-254).

[0109] Expression of the *gshA* gene can be attenuated by replacing an expression control sequence of the gene, such as a promoter on the chromosomal DNA, with a weaker one. The strength of a promoter is defined by the frequency of initiation acts of RNA synthesis. Examples of methods for evaluating the strength of promoters and strong promoters are described in Goldstein M.A. et al. (Goldstein M.A. and Doi R.H., Prokaryotic promoters in biotechnology, Biotechnol. Annu. Rev., 1995, 1:105-128), and so forth. Furthermore, it is also possible to introduce one or more nucleotide substitutions in a promoter region of the gene and thereby modify the promoter to be weakened as disclosed in WO0018935 A1. Furthermore, it is known that substitution of several nucleotides in the Shine-Dalgarno (SD) sequence, and/or in the spacer between the SD sequence and the start codon, and/or a sequence immediately upstream and/or downstream from the start codon in the ribosome-binding site (RBS) greatly affects the translation efficiency of mRNA. This modification of such a region may be combined with decreasing transcription of the *gshA* gene.

[0110] Expression of the *gshA* gene can also be attenuated by inserting a transposon or an insertion sequence (IS) into the coding region of the gene (U.S. Patent No. 5,175,107) or in the region controlling gene expression, or by conventional methods such as mutagenesis with ultraviolet (UV) irradiation or nitrosoguanidine (N-methyl-N'-nitro-N-nitrosoguanidine, NTG). Furthermore, the incorporation of a site-specific mutation can be conducted by known chromosomal editing methods based, for example, on λ Red/ET-mediated recombination (Datsenko K.A. and Wanner B.L., Proc. Natl. Acad. Sci. USA, 2000, 97(12):6640-6645).

[0111] The copy number, presence or absence of the *gshA* gene can be measured, for example, by restricting the chromosomal DNA followed by Southern blotting using a probe based on the gene sequence, fluorescence *in situ* hybridization (FISH), and the like. The level of gene expression can be determined by measuring the amount of mRNA transcribed from the gene using various well-known methods, including Northern blotting, quantitative RT-PCR, and the like. The amount of the protein encoded by the gene can be measured by known methods including SDS-PAGE followed by immunoblotting assay (Western blotting analysis), or mass spectrometry analysis of the protein samples, and the like.

[0112] Methods for manipulation with recombinant molecules of DNA and molecular cloning such as preparation of plasmid DNA, digestion, ligation and transformation of DNA, selection of an oligonucleotide as a primer, incorporation of mutations, and the like may be ordinary methods well-known to the person skilled in the art. These methods are described, for example, in Sambrook J., Fritsch E.F. and Maniatis T., "Molecular Cloning: A Laboratory Manual", 2nd ed., Cold Spring Harbor Laboratory Press (1989) or Green M.R. and Sambrook J.R., "Molecular Cloning: A Laboratory Manual", 4th ed., Cold Spring Harbor Laboratory Press (2012); Bernard R. Glick, Jack J. Pasternak and Cheryl L. Patten, "Molecular Biotechnology: principles and applications of recombinant DNA", 4th ed., Washington, DC, ASM Press (2009).

[0113] There may be some differences in DNA sequences between the genera, species, or strains of the family *Enterobacteriaceae*. Therefore, the *gshA* gene is not limited to the gene shown in SEQ ID NO: 1, but may include genes which are variant nucleotide sequences of SEQ ID NO: 1, and which encode the γ GCS protein. That is, the phrase "the *gshA* gene" is not limited to the *gshA* gene shown in SEQ ID NO: 1, but can correctively refer to the *gshA* gene shown in SEQ ID NO: 1 and variant nucleotide sequences thereof.

[0114] Similarly, the phrase "the γ GCS" or "the γ GCS protein" is not limited to the γ GCS protein shown in SEQ ID NO: 2, but can correctively refer to the γ GCS protein shown in SEQ ID NO: 2 and variant proteins thereof.

[0115] The phrase "a variant protein" can mean a protein which has one or more mutations in the sequence compared with SEQ ID NO: 2, whether they are substitutions, deletions, insertions, and/or additions of one or several amino acid residues, but which still maintains an activity or function similar to that of the γ GCS protein, such as the activity of γ -glutamate-cysteine ligase as described above, or of which the three-dimensional structure is not significantly changed relative to the wild-type protein. The number of changes in the variant protein depends on the position of amino acid residues in the three-dimensional structure of the protein or the type of amino acid residues. It can be, but is not strictly limited to, 1 to 100, in another example 1 to 50, in another example 1 to 30, in another example 1 to 15, in another example 1 to 10, and in another example 1 to 5, in SEQ ID NO: 2. This is because some amino acids have high homology to one another, so that the activity or function of a protein is not affected by a change between such amino acids, or the three-dimensional structure of a protein is not significantly changed relative to the wild-type protein by a change between such amino acids. Therefore, the variant proteins encoded by the *gshA* gene may have a homology, defined as the parameter "identity" when using the computer program BLAST, of not less than 65%, not less than 70%, not less than 75%, not less than 80%, not less than 85%, not less than 90%, not less than 95%, not less than 98%, or not less than 99% with respect to the entire amino acid sequence shown in SEQ ID NO: 2, as long as the activity or function of the γ GCS protein is maintained, or the three-dimensional structure of γ GCS protein is not significantly changed relative to the wild-type γ GCS protein.

[0116] The exemplary substitution, deletion, insertion, and/or addition of one or several amino acid residues can be a conservative mutation(s). The representative conservative mutation is a conservative substitution. The conservative substitution can be, but is not limited to, a substitution, wherein substitution takes place mutually among Phe, Trp and Tyr, if the substitution site is an aromatic amino acid; among Ala, Leu, Ile and Val, if the substitution site is a hydrophobic amino acid; between Glu, Asp, Gln, Asn, Ser, His and Thr, if the substitution site is a hydrophilic amino acid; between Gln and Asn, if the substitution site is a polar amino acid; among Lys, Arg and His, if the substitution site is a basic amino

acid; between Asp and Glu, if the substitution site is an acidic amino acid; and between Ser and Thr, if the substitution site is an amino acid having hydroxyl group. Examples of conservative substitutions include substitution of Ser or Thr for Ala, substitution of Gln, His or Lys for Arg, substitution of Glu, Gln, Lys, His or Asp for Asn, substitution of Asn, Glu or Gln for Asp, substitution of Ser or Ala for Cys, substitution of Asn, Glu, Lys, His, Asp or Arg for Gln, substitution of Asn, Gln, Lys or Asp for Glu, substitution of Pro for Gly, substitution of Asn, Lys, Gln, Arg or Tyr for His, substitution of Leu, Met, Val or Phe for Ile, substitution of Ile, Met, Val or Phe for Leu, substitution of Asn, Glu, Gln, His or Arg for Lys, substitution of Ile, Leu, Val or Phe for Met, substitution of Trp, Tyr, Met, Ile or Leu for Phe, substitution of Thr or Ala for Ser, substitution of Ser or Ala for Thr, substitution of Phe or Tyr for Trp, substitution of His, Phe or Trp for Tyr, and substitution of Met, Ile or Leu for Val.

[0117] The exemplary substitution, deletion, insertion, and/or addition of one or several amino acid residues can also be a non-conservative mutation(s) provided that the mutation(s) is/are compensated by one or more secondary mutations in the different position(s) of amino acids sequence so that the activity or function similar to that of the γ GCS protein, such as the activity of γ -glutamate-cysteine ligase as described above, is maintained, or the three-dimensional structure of γ GCS protein is not significantly changed relative to the wild-type γ GCS protein.

[0118] To evaluate the degree of protein or DNA homology, several calculation methods can be used, such as BLAST search, FASTA search and ClustalW method. The BLAST (Basic Local Alignment Search Tool, www.ncbi.nlm.nih.gov/BLAST/) search is the heuristic search algorithm employed by the programs blastp, blastn, blastx, megablast, tblastn, and tblastx; these programs ascribe significance to their findings using the statistical methods of Karlin S. and Altschul S.F. (Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes, Proc. Natl. Acad. Sci. USA, 1990, 87:2264-2268; Applications and statistics for multiple high-scoring segments in molecular sequences, Proc. Natl. Acad. Sci. USA, 1993, 90:5873-5877). The computer program BLAST calculates three parameters: score, identity and similarity. The FASTA search method is described by Pearson W.R. (Rapid and sensitive sequence comparison with FASTP and FASTA, Methods Enzymol., 1990, 183:63-98). The ClustalW method is described by Thompson J.D. et al. (CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice, Nucleic Acids Res., 1994, 22:4673-4680).

[0119] Examples of variant proteins of the γ GCS protein shown in SEQ ID NO: 2 include protein homologues of γ GCS (γ GCS homologues) from different bacteria of the family *Enterobacteriaceae*. That is, γ GCS homologues from different bacteria of the family *Enterobacteriaceae* are known, that have the activity of γ -glutamate-cysteine ligase as described above. Examples of such γ GCS homologues from the bacteria belonging to the family *Enterobacteriaceae* are described hereinafter (Table 1) with indication of a homology value (as "identity", that is the identity of amino acids), taxonomy data, and accession and sequence record numbers of amino acid sequences in the NCBI database (National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/protein/>).

Table 1.

Identity	Organism	Accession No.*; Sequence record (GI) No.*
100%	<i>Escherichia coli</i> (strain K-12)	NP_417173.1; GI:16130600
87%	<i>Klebsiella pneumoniae</i>	CDO12865.1; GI:597513774
99%	<i>Shigella sonnei</i>	WP_000611798.1; GI:446534452
94%	<i>Salmonella enterica</i>	WP_000611815.1; GI:446534469
87%	<i>Enterobacter aerogenes</i>	WP_032712382.1; GI:695798191
67%	<i>Pantoea ananatis</i> (strain AJ 13355)	BAK12383.1; GI:327394961
87%	<i>Klebsiella pneumoniae</i>	KGZ19147.1; GI:721575847
73%	<i>Pantoea</i> sp. IMH	WP_033758687.1; GI:727301739

(continued)

Identity	Organism	Accession No.*; Sequence record (GI) No.*
68%	<i>Erwinia amylovora</i> (strain ATCC BAA-2158)	CBX79664.1; GI:312171405
76%	<i>Serratia liquefaciens</i>	WP_044554246.1; GI:764987737
99%	<i>Shigella flexneri</i>	WP_000611805.1; GI:446534459
68%	<i>Morganella morganii</i>	WP_036426159.1; GI:738475870
73%	<i>Dickeya dadantii</i>	WP_013319093.1; GI:503084223
* - in the NCBI database (National Center for Biotechnology Information, www.ncbi.nlm.nih.gov/)		

[0120] The *gshA* gene can be any gene encoding the γ GCS protein. For example, the *gshA* gene can be a variant nucleotide sequence. The phrase "a variant nucleotide sequence" can mean a nucleotide sequence which encodes "a variant protein" as described above, or a nucleotide sequence which encodes any wild-type γ GCS protein such as the γ GCS protein shown in SEQ ID NO: 2 using any synonymous amino acid codons according to the standard genetic code table (see, e.g., Lewin B., "Genes VIII", 2004, Pearson Education, Inc., Upper Saddle River, NJ 07458). Therefore, the *gshA* gene can be a variant nucleotide sequence due to the degeneracy of the genetic code such as a variant nucleotide sequence of SEQ ID NO: 1 due to the degeneracy of the genetic code.

[0121] The phrase "a variant nucleotide sequence" can also mean, but is not limited to, a nucleotide sequence which hybridizes under stringent conditions with the nucleotide sequence complementary to the sequence shown in SEQ ID NO: 1 or a probe which can be prepared from the nucleotide sequence under stringent conditions provided that it encodes a functional protein. "Stringent conditions" include those under which a specific hybrid, for example, a hybrid having homology, defined as the parameter "identity" when using the computer program BLAST, of not less than 60%, not less than 65%, not less than 70%, not less than 75%, not less than 80%, not less than 85%, not less than 90%, not less than 95%, not less than 96%, not less than 97%, not less than 98%, or not less than 99% is formed, and a non-specific hybrid, for example, a hybrid having homology lower than the above is not formed. For example, stringent conditions can be exemplified by washing one time or more, or in another example, two or three times, at a salt concentration of $1\times$ SSC (standard sodium citrate or standard sodium chloride), 0.1% SDS (sodium dodecyl sulphate), or in another example, $0.1\times$ SSC, 0.1% SDS at 60°C or 65°C. Duration of washing depends on the type of membrane used for blotting and, as a rule, can be what is recommended by the manufacturer. For example, the recommended duration of washing for the Amersham Hybond™-N+ positively charged nylon membrane (GE Healthcare) under stringent conditions is 15 minutes. The washing step can be performed 2 to 3 times. As the probe, a part of the sequence complementary to the sequence shown in SEQ ID NO: 1 may also be used. Such a probe can be produced by PCR using oligonucleotides as primers prepared on the basis of the sequence shown in SEQ ID NO: 1 and a DNA-fragment containing the nucleotide sequence as a template. The length of the probe is recommended to be >50 bp; it can be suitably selected depending on the hybridization conditions, and is usually 100 bp to 1 kbp. For example, when a DNA-fragment having a length of about 300 bp is used as the probe, the washing conditions after hybridization can be exemplified by $2\times$ SSC, 0.1% SDS at 50°C, 60°C or 65°C.

[0122] As the gene encoding the γ GCS protein of the species *E. coli* has already been elucidated (see above), the variant nucleotide sequences encoding the γ GCS protein can be obtained by PCR (polymerase chain reaction; refer to White T.J. et al., The polymerase chain reaction, Trends Genet., 1989, 5:185-189) utilizing primers prepared based on the nucleotide sequence of the *gshA* gene; or the site-directed mutagenesis method by treating a DNA containing the wild-type *gshA* gene *in vitro*, for example, with hydroxylamine, or a method for treating a microorganism, for example, a bacterium belonging to the family *Enterobacteriaceae* harboring the wild-type *gshA* gene with ultraviolet (UV) irradiation or a mutating agent such as N-methyl-N'-nitro-N-nitrosoguanidine (NTG) and nitrous acid usually used for the such treatment; or chemically synthesized as full-length gene structure. That is, genes encoding the γ GCS protein of other bacteria of the family *Enterobacteriaceae* can be thus obtained.

[0123] The phrase "a wild-type protein" can mean a native protein naturally produced by a wild-type or parent bacterial strain of the family *Enterobacteriaceae*, for example, by the wild-type *E. coli* MG1655 strain. A wild-type protein can be

encoded by the "wild-type gene", which can be present in genome of a wild-type bacterium.

[0124] The above descriptions concerning variants of the genes and proteins can also be applied *mutatis mutandis* to arbitrary proteins such as L-amino acid biosynthesis enzymes and genes coding for them.

[0125] The bacterium can have, in addition to the properties already mentioned, other specific properties such as various nutrient requirements, drug resistance, drug sensitivity, and drug dependence, without departing from the scope of the present invention.

2. Method

[0126] A method of the present invention includes the method for producing an L-amino acid such as L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-citrulline, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-ornithine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine, or a mixture thereof. Specifically, a method of the present invention includes the method for producing branched-chain L-amino acids, such as L-isoleucine, L-leucine, and L-valine, or a mixture thereof. More specifically, a method of the present invention includes the method for producing L-valine.

[0127] The method for producing an L-amino acid can include the steps of cultivating the bacterium as described herein in a culture medium to allow the L-amino acid to be produced, excreted, and/or accumulated in the culture medium or in the bacterial cells, or both, and collecting the L-amino acid from the culture medium and/or the bacterial cells. Collected amino acid can be further purified. The target L-amino acid can be produced in a free form, a salt form or a hydrate form thereof, or an adduct form thereof with another organic or inorganic compound, or as a combination thereof. That is, the phrase "L-amino acid" may refer to an L-amino acid in a free form, a salt form thereof, a hydrate form thereof, an adduct form thereof, or a mixture thereof. Also, the phrase "L-amino acid" may specifically refer to an L-amino acid in a free form, a salt form thereof, or a mixture thereof. For example, ammonium, sodium, potassium, and the like salts or an inner salt such as zwitterion of the L-amino acid can be produced by the method. This is possible as amino acids can react under fermentation conditions with each other or a neutralizing agent such as an inorganic or organic acidic or alkaline substance in a typical acid-base neutralization reaction to form a salt that is the chemical feature of amino acids which is apparent to one skilled in the art. Specifically, a monochlorhydrate salt of an L-amino acid can be produced by the method such as monochlorhydrate salt of L-lysine (L-lysine-HCl) or monochlorhydrate salt of L-arginine (L-arginine-HCl); or monochlorhydrate salt monohydrate of an L-amino acid can be produced by the method such as monochlorhydrate monohydrate of L-histidine (L-histidine-HCl-H₂O).

[0128] The cultivation of the bacterium, and collection and purification of L-amino acids may be performed in a manner similar to conventional fermentation methods wherein an L-amino acid is produced using a microorganism. The culture medium for production of the L-amino acid can be either a synthetic or natural medium such as a typical medium that contains a carbon source, a nitrogen source, a sulphur source, a phosphorous source, inorganic ions, and other organic and inorganic components as required. As the carbon source, saccharides such as glucose, lactose, galactose, fructose, arabinose, maltose, xylose, trehalose, ribose, sucrose, and hydrolysates of starches; alcohols such as ethanol, glycerol, mannitol, and sorbitol; organic acids such as gluconic acid, fumaric acid, citric acid, malic acid, and succinic acid; fatty acids; and the like can be used. As the nitrogen source, inorganic ammonium salts such as ammonium sulfate, ammonium chloride, and ammonium phosphate; organic nitrogen such as of soy bean hydrolyzates; ammonia gas; aqueous ammonia; and the like can be used. Furthermore, peptone, yeast extract, meat extract, malt extract, corn steep liquor, and so forth can also be utilized. The sulphur source can include ammonium sulphate, magnesium sulphate, ferrous sulphate, manganese sulphate, and the like. The medium can contain a phosphorus source in addition to the carbon source, the nitrogen source, and the sulphur source. As the phosphorus source, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, phosphate polymers such as pyrophosphoric acid and so forth can be utilized. Vitamins such as vitamin B1, vitamin B2, vitamin B6, nicotinic acid, nicotinamide, and vitamin B12; required substances, for example, organic nutrients such as nucleic acids such as adenine and RNA, amino acids, peptone, casamino acid, or yeast extract; and the like may be present in appropriate, even if trace, amounts. Other than these, small amounts of calcium phosphate, iron ions, manganese ions, and the like may be added, if necessary.

[0129] Cultivation can be performed under aerobic conditions for 16 to 72 h, or for 16 to 65 h; the culture temperature during cultivation can be controlled within 30 to 45°C, or within 30 to 37°C; and the pH can be adjusted between 5 and 8, or between 6.0 and 7.5. The pH can be adjusted by using an inorganic or organic acidic or alkaline substance, as well as ammonia gas.

[0130] After cultivation, the target L-amino acid can be collected from the culture medium. Also, after cultivation, the cells can be disrupted with, for example, supersonic waves or the like, the supernatant can be obtained by removing solids such as the cells and the cell-disrupted suspension (also referred to as cell debris) by, for example, centrifugation or membrane filtration, and then the target L-amino acid can be collected from the supernatant. Collection of L-amino acid from the culture medium or the supernatant *etc* can be performed by any combination of conventional techniques such as concentration, ion-exchange chromatography, and crystallization.

[0131] The collected target L-amino acid composition may contain microbial cells, medium components, moisture, and by-product metabolites of the microorganism in addition to the target L-amino acid. Purity of the collected target L-amino acid can be 50% or higher, preferably 85% or higher, particularly preferably 95% or higher (U.S. Patent No. 5,431,933, Japanese Patent No. 1214636, U.S. Patent Nos. 4,956,471, 4,777,051, 4,946,654, 5,840,358, 6,238,714, U.S. Patent Published Application No. 2005/0025878).

Examples

[0132] The present invention will be more specifically explained below with reference to the following non-limiting examples.

Example 1. Construction of the *E. coli* strain having an inactivated *gshA* gene 1.1. Construction of *E. coli* MG1655Δ*gshA* strain

[0133] An *E. coli* strain having an inactivated *gshA* gene was constructed by the method initially developed by Datsenko K.A. and Wanner B.L. called "λRed/ET-mediated integration" (Datsenko K.A. and Wanner B.L., Proc. Natl. Acad. Sci. USA, 2000, 97(12):6640-6645). According to this method, the PCR-primers P1 (SEQ ID NO: 3) and P2 (SEQ ID NO: 4), each of which is homologous to a region adjacent to the *gshA* gene at either end, and a region adjacent to the *cat* gene conferring chloramphenicol resistance (Cm^R) in the template plasmid at the other end, were constructed. The plasmid pMIV-5JS (JP2008-99668, EP1942183 A1) was used as the template. Conditions for PCR were as follows: denaturation for 3 min at 95°C; profile for the initial 2 cycles: 1 min at 95°C, 30 sec at 34°C, 1 min at 72°C; profile for the final 30 cycles: 30 sec at 95°C, 30 sec at 50°C, 1 min at 72°C; final elongation: 5 min at 72°C.

[0134] The obtained PCR-product 1 (SEQ ID NO: 5; 1,378 bp) was purified by electrophoresis in agarose gel and used for electroporation of the *E. coli* MG1655 strain containing the pKD46 plasmid having a temperature-sensitive replication origin. The pKD46 plasmid (Datsenko K.A. and Wanner B.L., Proc. Natl. Acad. Sci. USA, 2000, 97(12):6640-6645) includes a 2,154 nucleotides DNA-fragment of phage λ (nucleotide positions from 31088 to 33241; GenBank, accession No. J02459), and thus contains genes of the λRed homologous recombination system (γ, β, and exo genes) under the control of the arabinose-inducible P_{araB} promoter. The pKD46 plasmid is necessary for integration of the PCR-product into the chromosome of the *E. coli* MG1655 strain (ATCC 47076). The *E. coli* MG1655 strain containing the pKD46 plasmid can be obtained from the *E. coli* Genetic Stock Center, Yale University, New Haven, USA (Accession No. CGSC7669).

[0135] Electrocompetent cells were prepared as follows: *E. coli* MG1655/pKD46 was grown overnight at 30°C in LB-medium (Luria-Bertani broth, also referred to as lysogenic broth; Sambrook J. and Russell D.W., Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press, 2001) containing ampicillin (100 mg/L); then the culture was diluted 100 times with 5 mL of SOB-medium (Sambrook J., Fritsch E.F. and Maniatis T., Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, 1989) containing ampicillin (100 mg/L) and L-arabinose (1 mM). The diluted culture was grown with aeration (250 rpm) at 30°C to OD₆₀₀ of about 0.6 and then made electrocompetent by concentrating 100-fold and washing three times with ice-cold deionized H₂O. Electroporation was performed using 70 μL of cells and about 100 ng of the PCR-product 1. Electroporated cells were incubated with 1 mL of SOC-medium (Sambrook J. et al., Molecular Cloning: A Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, 1989) at 37°C for 2.5 hours, placed onto the plates containing the lysogenic broth (Sambrook J. and Russell D.W., Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press, 2001), agar (1.5%) and chloramphenicol (10 mg/L), and grown at 37°C to select Cm^R-recombinants. To eliminate the pKD46 plasmid, two passages on L-agar supplemented with chloramphenicol (10 mg/L) at 42°C were performed, and the obtained colonies were tested for sensitivity to ampicillin. Thus the *E. coli* MG1655Δ*gshA* strain having the Cm^R-marker, which is also referred to as the *E. coli* MG1655Δ*gshA*::Cm^R strain, was obtained.

1.2. Verification of deletion of the *gshA* gene

[0136] The deletion of *gshA* gene marked with chloramphenicol resistance gene (*cat*) in the mutant *E. coli* MG1655Δ*gshA* strain was verified by PCR. Locus-specific primers P3 (SEQ ID NO: 6) and P4 (SEQ ID NO: 7) were used for the verification. Conditions for PCR were as follows: denaturation for 3 min at 94°C; profile for the 30 cycles: 30 sec at 94°C, 30 sec at 58°C, 2 min at 72°C; final elongation: 6 min at 72°C. The PCR-product 2, obtained in the reaction with the chromosomal DNA as the template from the parental strain *E. coli* MG1655 having native *gshA* gene, was 2,155 bp in length (SEQ ID NO: 8). The PCR-product 3, obtained in the reaction with the chromosomal DNA as a template from the mutant strain *E. coli* MG1655Δ*gshA*::Cm^R, was 1,858 bp in length (SEQ ID NO: 9).

Example 2. Construction of the *E. coli* L-valine-producing strain having an inactivated *gshA* gene

[0137] To test the effect from inactivation of the *gshA* gene on L-valine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655Δ*gshA*::Cm^R strain (Example 1.1) were transferred to the valine-producing *E. coli* strain H81 by P1-transduction (Miller J.H., Experiments in Molecular Genetics, Cold Spring Harbor Lab. Press, Plainview, NY, 1972) to obtain the strain *E. coli* H81Δ*gshA*::Cm^R. The strain H81 (EP1239041 A2) was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on January 30, 2001 under the accession number VKPM B-8066 and then converted to an international deposit under the provisions of the Budapest Treaty on February 1, 2002. The *E. coli* H81 strain having the inactivated *gshA* gene was selected on the plates containing the lysogenic broth, agar (1.5%) and chloramphenicol (10 mg/L). Thus the *E. coli* H81Δ*gshA*::Cm^R strain was obtained. The deletion of *gshA* marked with chloramphenicol resistance gene was verified by PCR as described in Example 1.2.

Example 3. Production of L-valine by *E. coli* H81Δ*gshA*::Cm^R strain

[0138] The modified *E. coli* H81Δ*gshA*::Cm^R and the control *E. coli* H81 strains were separately cultivated in 2 mL of LB-medium for 18 hours at 34°C. Then, 0.2 mL of obtained cultures were each inoculated into 2 mL of fermentation medium in 20 × 200-mm test tubes and cultivated for 72 hours at 34°C on a rotary shaker (250 rpm) until glucose consumption.

[0139] The composition of the fermentation medium (g/L) was as follows:

Glucose	76.0
(NH ₄) ₂ SO ₄	18.0
KH ₂ PO ₄	1.8
MgSO ₄ ·7H ₂ O	1.2
Thiamine-HCl	0.1
CaCO ₃	24.0
LB-medium	10% (v/v)

[0140] The fermentation medium was sterilized at 116°C for 30 min. Glucose and CaCO₃ were sterilized separately as follows: glucose at 110°C for 30 min and CaCO₃ at 116°C for 30 min. The pH was adjusted to 7.0 by 6M KOH before sterilization.

[0141] After the cultivation, the amount of L-valine, which accumulated in the medium, was determined by thin layer chromatography (TLC). The 10 × 20-cm TLC plates coated with Merck silica gel 60 without fluorescent indicator (Merck, Darmstadt, Germany) were used. Samples were applied onto the plates using the Camag Linomat 5 sample applicator. The Merck plates were developed with a mobile phase consisting of propan-2-ol : ethyl acetate : 25% aqueous ammonia : water = 16 : 16 : 5 : 10 (v/v). A solution of ninhydrin (2%, w/v) in acetone was used as a visualizing reagent. After development, plates were dried and scanned with the Camag TLC Scanner 3 in absorbance mode with detection at 520 nm using winCATS software (version 1.4.2).

[0142] The results of four independent test-tube fermentations (as average values) are shown in Table 2. As it can be seen from the Table 2, the modified *E. coli* H81Δ*gshA*::Cm^R strain was able to produce a higher amount (g/L) of L-valine (Val) as compared with the parent *E. coli* H81 strain. Table 2 also shows that the modified *E. coli* H81Δ*gshA*::Cm^R strain was able to produce L-valine with higher yield (% relative to consumed glucose) as compared with the parent *E. coli* H81 strain.

Table 2.

Strain	OD ₆₀₀	Val, g/L	Val yield, %
<i>E. coli</i> H81 (control)	32 ± 2	7.1 ± 0.5	9.3 ± 0.7
<i>E. coli</i> H81Δ <i>gshA</i> ::Cm ^R	28 ± 1	8.4 ± 0.5	11.0 ± 0.7

Example 4. Production of L-arginine by *E. coli* 382Δ*gshA* strain

[0143] To test the effect from inactivation of the *gshA* gene on L-arginine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655Δ*gshA*::Cm^R are transferred to the arginine-producing *E. coli* strain 382 by P1-transduction to obtain the strain *E. coli* 382Δ*gshA*. The strain 382 was deposited in the Russian National

EP 3 098 319 A1

Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on April 10, 2000 under the accession number VKPM B-7926 and then converted to an international deposit under the provisions of the Budapest Treaty on May 18, 2001.

[0144] *E. coli* strains 382 and 382ΔgshA are separately cultivated with shaking (220 rpm) at 37°C for 18 hours in 3 mL of nutrient broth. Then, 0.3 mL of the obtained cultures are each inoculated into 2 mL of fermentation medium in 20 × 200-mm test tubes and cultivated at 32°C for 48 hours on a rotary shaker (220 rpm).

[0145] After the cultivation, the amount of L-arginine which accumulates in the medium is determined by paper chromatography using a mobile phase consisting of n-butanol : acetic acid : water = 4 : 1 : 1 (v/v). A solution of ninhydrin (2%) in acetone is used as a visualizing reagent. A spot containing L-arginine is cut out, L-arginine is eluted with 0.5% water solution of CdCl₂, and the amount of L-arginine is estimated spectrophotometrically at 540 nm.

[0146] The composition of the fermentation medium (g/L) is as follows:

Glucose	48.0
(NH ₄) ₂ SO ₄	35.0
KH ₂ PO ₄	2.0
MgSO ₄ ·7H ₂ O	1.0
Thiamine-HCl	0.0002
Yeast extract	1.0
L-isoleucine	0.1
CaCO ₃	5.0

[0147] Glucose and magnesium sulfate are sterilized separately. CaCO₃ is dry-heat sterilized at 180°C for 2 h. The pH is adjusted to 7.0.

Example 5. Production of L-citrulline by *E. coli* 382ΔargGΔgshA

[0148] To test the effect from inactivation of the *gshA* gene on L-citrulline production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R strain are transferred to the citrulline-producing *E. coli* strain 382ΔargG by P1-transduction to obtain the strain *E. coli* 382ΔargGΔgshA. The strain 382ΔargG is obtained by deletion of *argG* gene on the chromosome of the arginine-producing *E. coli* strain 382 (VKPM B-7926, EP1170358 A1) by the method initially developed by Datsenko K.A. and Wanner B.L. called "λRed/ET-mediated integration" (Datsenko K.A. and Wanner B.L., Proc. Natl. Acad. Sci. USA, 2000, 97(12):6640-6645). According to this procedure, the PCR-primers, each of which is homologous to both a region adjacent to the *argG* gene and a region adjacent to the gene which confers antibiotic resistance in the template plasmid, are constructed. The plasmid pMW118-λattL-cat-λattR (WO05/010175) is used as the template in the PCR.

[0149] *E. coli* strains 382ΔargG and 382ΔargGΔgshA are separately cultivated with shaking at 37°C for 18 hours in 3 mL of nutrient broth. Then, 0.3 mL of the obtained cultures are each inoculated into 2 mL of fermentation medium in 20 × 200-mm test tubes and cultivated at 32°C for 48 hours on a rotary shaker.

[0150] After the cultivation, the amount of L-citrulline which accumulates in the medium is determined by paper chromatography using a mobile phase consisting of butan-1-ol : acetic acid : water = 4 : 1 : 1 (v/v). A solution of ninhydrin (2%) in acetone is used as a visualizing reagent. A spot containing citrulline is cut out, L-citrulline is eluted with 0.5% water solution of CdCl₂, and the amount of L-citrulline is estimated spectrophotometrically at 540 nm.

[0151] The composition of the fermentation medium (g/L) is as follows:

Glucose	48.0
(NH ₄) ₂ SO ₄	35.0
KH ₂ PO ₄	2.0
MgSO ₄ ·7H ₂ O	1.0
Thiamine-HCl	0.0002
Yeast extract	1.0
L-Isoleucine	0.1
L-Arginine	0.1
CaCO ₃	5.0

[0152] Glucose and magnesium sulfate are sterilized separately. CaCO₃ is dry-heat sterilized at 180°C for 2 h. The

pH is adjusted to 7.0.

Example 6. Production of L-cysteine by *E. coli* JM15(ydeD) Δ gshA

[0153] To test the effect from inactivation of the *gshA* gene on L-cysteine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655 Δ gshA::Cm^R strain are transferred to the cysteine-producing *E. coli* strain JM15(ydeD) by P1-transduction to obtain the strain *E. coli* JM15(ydeD) Δ gshA. The strain JM15(ydeD) is a derivative of *E. coli* JM15 (U.S. Patent No. 6,218,168 B1), which has been transformed with DNA containing the *ydeD* gene (U.S. Patent No. 5,972,663). The *ydeD* gene encodes a membrane protein, and it is not involved in a biosynthetic pathway of any L-amino acid.

[0154] Fermentation conditions and procedure for evaluation of L-cysteine production were described in detail in Example 6 of U.S. Patent No. 6,218,168 B1.

Example 7. Production of L-glutamic acid by *E. coli* VL334thrC⁺ Δ gshA

[0155] To test the effect from inactivation of the *gshA* gene on L-glutamic acid production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655 Δ gshA::Cm^R strain are transferred to the glutamate-producing *E. coli* strain VL334thrC⁺ (EP1172433 A1) by P1-transduction to obtain the strain *E. coli* VL334thrC⁺ Δ gshA. The strain VL334thrC⁺ was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1 Dorozhny proezd, 1) on December 6, 2004 under the accession number VKPM B-8961 and then converted to an international deposit under the provisions of the Budapest Treaty on December 8, 2004.

[0156] *E. coli* strains VL334thrC⁺ and VL334thrC⁺ Δ gshA are separately cultivated for 18-24 hours at 37°C on L-agar plates. Then, one loop of the cells is transferred into 20 x 200-mm test tubes containing 2 mL of fermentation medium. Cultivation is carried out at 30°C for 3 days with shaking.

[0157] After the cultivation, the amount of L-glutamic acid which accumulates in the medium is determined by paper chromatography using a mobile phase consisting of butan-1-ol : acetic acid : water = 4 : 1 : 1 (v/v) with subsequent staining by ninhydrin (1% solution in acetone), elution of L-glutamic acid in 50% ethanol with 0.5% CdCl₂ and further estimation of the amount of L-glutamic acid at 540 nm.

[0158] The composition of the fermentation medium (g/L) is as follows:

Glucose	60.0
(NH ₄) ₂ SO ₄	25.0
KH ₂ PO ₄	2.0
MgSO ₄ ·7H ₂ O	1.0
Thiamine-HCl	0.1
L-Isoleucine	0.07
CaCO ₃	25.0

[0159] Glucose and CaCO₃ are sterilized separately. The pH is adjusted to 7.2.

Example 8. Production of L-histidine by *E. coli* MG1655+hisG⁺ hisL'_Δ Δ purR Δ gshA

[0160] To test the effect from inactivation of the *gshA* gene on L-histidine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655 Δ gshA::Cm^R strain are transferred to the L-histidine-producing *E. coli* strain MG1655+hisG⁺ hisL'_Δ Δ purR using the P1-transduction to obtain the strain *E. coli* MG1655+hisG⁺ hisL'_Δ Δ purR Δ gshA. The strain MG1655+hisG⁺ hisL'_Δ Δ purR was described in RU2119536 C1 and Doroshenko V.G. et al., The directed modification of Escherichia coli MG1655 to obtain histidine-producing mutants, Prikl. Biochim. Mikrobiol. (Russian), 2013, 49(2):149-154.

[0161] *E. coli* strains MG1655+hisG⁺ hisL'_Δ Δ purR and MG1655+hisG⁺ hisL'_Δ Δ purR Δ gshA are separately cultivated for 3 hours at 30°C in 2 mL of L-broth (Sambrook J. and Russell D.W., Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press, 2001). Then, 0.1 mL of the obtained cultures are each inoculated into 2 mL of fermentation medium in 20 x 200-mm test tubes and cultivated for 65 hours at 30°C on a rotary shaker (250 rpm).

[0162] The composition of the fermentation medium (g/L) is as follows:

Glucose	50.0
---------	------

(continued)

	Mameno*	0.2 (as the amount of nitrogen)
	L-aspartate	1.0
5	(NH ₄) ₂ SO ₄	18.0
	KCl	1.0
	KH ₂ PO ₄	0.5
	MgSO ₄ ·7H ₂ O	0.4
10	FeSO ₄ ·7H ₂ O	0.02
	MnSO ₄ ·5H ₂ O	0.02
	ZnSO ₄ ·7H ₂ O	0.02
	Adenosine	0.2
	Thiamine-HCl	0.001
15	Betaine	2.0
	CaCO ₃	60.0

*Mameno is the soybean meal hydrolysate (Ajinomoto Co, Inc.).

[0163] Glucose, magnesium sulphate, betaine, and CaCO₃ are sterilized separately. The pH is adjusted to 6.0 by 6M KOH solution before sterilization.

[0164] After the cultivation, the amount of L-histidine which accumulates in the medium is determined by thin layer chromatography (TLC). The 10 x 15-cm TLC plates coated with 0.11-mm layers of Sorbfil silica gel containing non-fluorescent indicator (Stock Company Sorbpolymer, Krasnodar, Russian Federation) are used. The Sorbfil plates are developed with a mobile phase consisting of propan-2-ol : acetone : 25% aqueous ammonia : water = 6 : 6 : 1.5 : 1 (v/v). A solution of ninhydrin (2%, w/v) in acetone is used as a visualizing reagent. After development, plates are dried and scanned with the Camag TLC Scanner 3 in absorbance mode with detection at 520 nm using winCATS software (version 1.4.2).

Example 9. Production of L-leucine by *E. coli* 57ΔgshA

[0165] To test the effect from inactivation of the *gshA* gene on L-leucine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R strain are transferred to the leucine-producing *E. coli* strain 57 (VKPM B-7386, U.S. Patent No. 6,124,121) by P1-transduction to obtain the strain *E. coli* 57ΔgshA. The strain 57 was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on May 19, 1997 under the accession number VKPM B-7386.

[0166] *E. coli* strains 57 and 57ΔgshA are separately cultivated for 18-24 hours at 37°C on L-agar plates. To obtain a seed culture, the strains are each grown on a rotary shaker (250 rpm) at 32°C for 18 hours in 20 x 200-mm test tubes containing 2 mL of L-broth (Sambrook J. and Russell D.W., Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press, 2001) supplemented with sucrose (4%). Then, the fermentation medium is inoculated with 0.2 mL of seed culture (10%). The fermentation is performed in 2 mL of a minimal fermentation medium in 20 x 200-mm test tubes. Cells are grown for 48-72 hours at 32°C with shaking at 250 rpm.

[0167] After the cultivation, the amount of L-leucine which accumulates in the medium is determined by paper chromatography using a mobile phase consisting of butan-1-ol : acetic acid : water = 4 : 1 : 1 (v/v).

[0168] The composition of the fermentation medium (g/L) is as follows:

	Glucose	60.0
	(NH ₄) ₂ SO ₄	25.0
50	K ₂ HPO ₄	2.0
	MgSO ₄ ·7H ₂ O	1.0
	Thiamine-HCl	0.01
	CaCO ₃	25.0

[0169] Glucose is sterilized separately. CaCO₃ is dry-heat sterilized at 180°C for 2 h. The pH is adjusted to 7.2.

Example 10. Production of L-lysine by *E. coli* AJ11442ΔgshA

[0170] To test the effect from inactivation of the *gshA* gene on L-lysine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R strain are transferred to the lysine-producing *E. coli* strain AJ11442 by P1-transduction to obtain the strain *E. coli* AJ11442ΔgshA. The strain AJ 11442 was deposited in National Institute of Bioscience and Human Technology of Agency of Industrial Science and Technology (currently, NITE IPOD, #120, 2-5-8 Kazusakamatari, Kisarazushi, Chiba-ken, 292-0818, Japan) on May 1, 1981 under the accession number of FERM P-5084 and then converted to an international deposit under the provisions of the Budapest Treaty on October 29, 1987 to be assigned an accession number of FERM BP-1543.

[0171] *E. coli* strains AJ 11442 and AJ11442ΔgshA are separately cultivated in L-medium containing streptomycin (20 mg/L) at 37°C. Then, 0.3 mL of the obtained cultures are each inoculated into 20 mL of fermentation medium containing the required drugs in a 500-mL flask. The cultivation is carried out at 37°C for 16 hours by using a reciprocal shaker at the agitation speed of 115 rpm.

[0172] After the cultivation, the amount of L-lysine which accumulates in the medium and residual glucose are determined by a known method (Biotechnalyzer AS210, Sakura Seiki Co.). Then, the yield of L-lysine is calculated relative to consumed glucose for each of the strains.

[0173] The composition of the fermentation medium (g/L) is as follows:

Glucose	40.0
(NH ₄) ₂ SO ₄	24.0
K ₂ HPO ₄	1.0
MgSO ₄ ·7H ₂ O	1.0
FeSO ₄ ·7H ₂ O	0.01
MnSO ₄ ·5H ₂ O	0.01
Yeast extract	2.0

[0174] The pH is adjusted to 7.0 by KOH, and the medium is autoclaved at 115°C for 10 min. Glucose and magnesium sulfate are sterilized separately. CaCO₃ is dry-heat sterilized at 180°C for 2 hours and added to the medium to a final concentration of 30 g/L.

Example 11. Production of L-ornithine by *E. coli* 382ΔargFΔargI,ΔgshA

[0175] To test the effect from inactivation of the *gshA* gene on L-ornithine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R strain are transferred to the ornithine-producing *E. coli* strain 382ΔargFΔargI by P1-transduction to obtain the strain *E. coli* 382ΔargFΔargI,ΔgshA. The strain 382AargFAargI is obtained by consecutive deletion of *argF* and *argI* genes on the chromosome of the arginine-producing *E. coli* strain 382 (VKPM B-7926, EP1170358 A1) by the method initially developed by Datsenko K.A. and Wanner B.L. called "λRed/ET-mediated integration" (Datsenko K.A. and Wanner B.L., Proc. Natl. Acad. Sci. USA, 2000, 97(12):6640-6645). According to this procedure, two pairs of PCR-primers homologous to both the region adjacent to the *argF* or *argI* gene and the gene which confers antibiotic resistance in the template plasmid are constructed. The plasmid pMW118-λattL-cat-λattR (WO05/010175) is used as the template in the PCR.

[0176] *E. coli* strains 382ΔargFΔargI and 382ΔargFΔargI,ΔgshA are separately cultivated with shaking at 37°C for 18 hours in 3 mL of nutrient broth. Then, 0.3 mL of the obtained cultures are each inoculated into 2 mL of fermentation medium in 20 x 200-mm test tubes and cultivated at 32°C for 48 hours on a rotary shaker.

[0177] After the cultivation, the amount of L-ornithine which accumulates in the medium is determined by paper chromatography using a mobile phase consisting of butan-1-ol : acetic acid : water = 4 : 1 : 1 (v/v). A solution of ninhydrin (2%) in acetone is used as a visualizing reagent. A spot containing ornithine is cut out, ornithine is eluted with 0.5% water solution of CdCl₂, and the amount of ornithine is estimated spectrophotometrically at 540 nm.

[0178] The composition of the fermentation medium (g/L) is as follows:

Glucose	48.0
(NH ₄) ₂ SO ₄	35.0
KH ₂ PO ₄	2.0
MgSO ₄ ·7H ₂ O	1.0
Thiamine-HCl	0.0002
Yeast extract	1.0

EP 3 098 319 A1

(continued)

L-Isoleucine	0.1
L-Arginine	0.1
CaCO ₃	5.0

[0179] Glucose and magnesium sulfate are sterilized separately. CaCO₃ is dry-heat sterilized at 180°C for 2 h. The pH is adjusted to 7.0.

Example 12. Production of L-phenylalanine by *E. coli* AJ12739ΔgshA

[0180] To test the effect from inactivation of the *gshA* gene on L-phenylalanine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R are transferred to the phenylalanine-producing *E. coli* strain AJ12739 by P1-transduction to obtain strain AJ12739ΔgshA. The strain AJ12739 was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on November 6, 2001 under the accession number VKPM B-8197 and then converted to an international deposit under the provisions of the Budapest Treaty on August 23, 2002.

[0181] *E. coli* strains AJ12739 and AJ12739ΔgshA are separately cultivated at 37°C for 18 hours in a nutrient broth. Then, 0.3 mL of the obtained cultures are each inoculated into 3 mL of fermentation medium in 20 x 200-mm test tubes and cultivated at 37°C for 48 hours with shaking on a rotary shaker.

[0182] After the cultivation, the amount of L-phenylalanine which accumulates in the medium is determined by thin layer chromatography (TLC). The 10 x 15-cm TLC plates coated with 0.11-mm layers of Sorbfil silica gel containing non-fluorescent indicator (Stock Company Sorbpolymers, Krasnodar, Russian Federation) are used. The Sorbfil plates are developed with a mobile phase consisting of propan-2-ol : ethyl acetate : 25% aqueous ammonia : water = 40 : 40 : 7 : 16 (v/v). A solution of ninhydrin (2%) in acetone is used as a visualizing reagent.

[0183] The composition of the fermentation medium (g/L) is as follows:

Glucose	40.0
(NH ₄) ₂ SO ₄	16.0
K ₂ HPO ₄	0.1
MgSO ₄ ·7H ₂ O	1.0
FeSO ₄ ·7H ₂ O	0.01
MnSO ₄ ·5H ₂ O	0.01
Thiamine-HCl	0.0002
Yeast extract	2.0
L-Tyrosine	0.125
CaCO ₃	20.0

[0184] Glucose and magnesium sulfate are sterilized separately. CaCO₃ is dry-heat sterilized at 180°C for 2 h. The pH is adjusted to 7.0.

Example 13. Production of L-proline by *E. coli* 702ilvAΔgshA

[0185] To test the effect from inactivation of the *gshA* gene on L-proline production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R strain are transferred to the proline-producing *E. coli* strain 702ilvA by P1-transduction to obtain the strain *E. coli* 702ilvAΔgshA. The strain 702ilvA was deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on July 18, 2000 under the accession number VKPM B-8012 and then converted to an international deposit under the provisions of the Budapest Treaty on May 18, 2001.

[0186] *E. coli* strains 702ilvA and 702ilvAΔgshA are separately cultivated for 18-24 hours at 37°C on L-agar plates. Then, these strains are each cultivated under the same conditions as in Example 7 (Production of L-glutamic acid).

Example 14. Production of L-threonine by *E. coli* B-3996ΔgshA

[0187] To test the effect from inactivation of the *gshA* gene on L-threonine production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655ΔgshA::Cm^R strain are transferred to the threonine-producing *E.*

coli strain VKPM B-3996 by P1-transduction to obtain the strain B-3996 Δ gshA. The strain VKPM B-3996 was deposited on November 19, 1987 in the All-Union Scientific Center of Antibiotics (Russian Federation, 117105 Moscow, Nagatinskaya Street, 3-A) under the accession number RIA 1867. The strain was also deposited in the Russian National Collection of Industrial Microorganisms (VKPM; FGUP GosNII Genetika, Russian Federation, 117545 Moscow, 1st Dorozhny proezd, 1) on December 19, 2002 under the accession number VKPM B-3996.

[0188] *E. coli* strains VKPM B-3996 and B-3996 Δ gshA are separately cultivated for 18-24 hours at 37°C on L-agar plates. To obtain a seed culture, the strains are each grown on a rotary shaker (250 rpm) at 32°C for 18 hours in 20 x 200-mm test tubes containing 2 mL of L-broth (Sambrook J. and Russell D.W., Molecular Cloning: A Laboratory Manual (3rd ed.), Cold Spring Harbor Laboratory Press, 2001) supplemented with glucose (4%). Then, the fermentation medium is inoculated with 0.2 mL (10%) of seed culture. The fermentation is performed in 2 mL of minimal medium in 20 x 200-mm test tubes. Cells are grown for 65 hours at 32°C with shaking at 250 rpm.

[0189] After the cultivation, the amount of L-threonine which accumulates in the medium is determined by paper chromatography using a mobile phase consisting of butan-1-ol : acetic acid : water = 4 : 1 : 1 (v/v). A solution of ninhydrin (2%) in acetone is used as a visualizing reagent. A spot containing L-threonine is cut out, L-threonine is eluted with 0.5% water solution of CdCl₂, and the amount of L-threonine is estimated spectrophotometrically at 540 nm.

[0190] The composition of the fermentation medium (g/L) is as follows:

Glucose	80.0
(NH ₄) ₂ SO ₄	22.0
NaCl	0.8
KH ₂ PO ₄	2.0
MgSO ₄ ·7H ₂ O	0.8
FeSO ₄ ·7H ₂ O	0.02
MnSO ₄ ·5H ₂ O	0.02
Thiamine-HCl	0.0002
Yeast extract	1.0
CaCO ₃	30.0

[0191] Glucose and magnesium sulfate are sterilized separately. CaCO₃ is sterilized by dry-heat at 180°C for 2 h. The pH is adjusted to 7.0. The antibiotic is introduced into the medium after sterilization.

Example 15. Production of L-tryptophan by *E. coli* SV164(pGH5) Δ gshA

[0192] To test the effect from inactivation of the *gshA* gene on L-tryptophan production, the DNA-fragments from the chromosome of the above-described *E. coli* MG1655 Δ gshA::Cm^R strain are transferred to the tryptophan-producing *E. coli* strain SV164(pGH5) by P1-transduction to obtain the strain *E. coli* SV164(pGH5) Δ gshA. The strain SV164(pGH5) is a strain obtained by introducing the plasmid pGH5 into the *E. coli* strain SV164. The strain SV164 (JP 3032013 B) has the *trpE* allele encoding anthranilate synthase free from feedback inhibition by tryptophan. The strain SV164 is a strain obtained by introducing a mutation into the *trpE* gene in the *E. coli* strain YMC9 (ATCC 33927). The strain YMC9 is available from the American Type Culture Collection (P.O. Box 1549, Manassas, VA 20108, United States of America). The plasmid pGH5 harbors a mutant *serA* gene encoding phosphoglycerate dehydrogenase free from feedback inhibition by serine. The strain SV164(pGH5) was described in detail in U.S. Patent No. 6,180,373 B1 or EP0662143 B1.

[0193] *E. coli* strains SV164(pGH5) and SV164(pGH5) Δ gshA are separately cultivated with shaking at 37°C for 18 hours in 3 mL of nutrient broth supplemented with tetracycline (20 mg/L, marker of pGH5 plasmid). Then, 0.3 mL of the obtained cultures are each inoculated into 3 mL of a fermentation medium containing tetracycline (20 mg/L) in 20 x 200-mm test tubes, and cultivated at 37°C for 48 hours on a rotary shaker at 250 rpm.

[0194] After the cultivation, the amount of L-tryptophan which accumulates in the medium is determined by TLC as described in Example 12 (Production of L-phenylalanine). The fermentation medium components are listed in Table 3, but should be sterilized in separate groups (A, B, C, D, E, F, G, and H), as shown, to avoid adverse interactions during sterilization.

Table 3.

Solutions	Component	Final concentration, g/L
A	KH ₂ PO ₄	1.5
	NaCl	0.5

EP 3 098 319 A1

(continued)

Solutions	Component	Final concentration, g/L
5	(NH ₄) ₂ SO ₄	1.5
	L-Methionine	0.05
	L-Phenylalanine	0.1
	L-Tyrosine	0.1
	Mameno* (as the amount of nitrogen)	0.07
10	B	Glucose
		MgSO ₄ ·7H ₂ O
15	C	CaCl ₂
	D	FeSO ₄ ·7H ₂ O
20		Sodium citrate
	E	Na ₂ MoO ₄ ·2H ₂ O
		H ₃ BO ₃
		CoCl ₂ ·6H ₂ O
		CuSO ₄ ·5H ₂ O
		MnCl ₂ ·4H ₂ O
		ZnSO ₄ ·7H ₂ O
25	F	Thiamine-HCl
	G	CaCO ₃
	H	Pyridoxine
The pH of solution A is adjusted to 7.1 with NH ₄ OH. *Mameno is the soybean meal hydrolysate (Ajinomoto Co., Inc.).		

[0195] While the invention has been described in detail with reference to preferred embodiments thereof, it will be apparent to one skilled in the art that various changes can be made, and equivalents employed, without departing from the scope of the invention. All the cited references herein are incorporated by reference as a part of this application.

Industrial Applicability

[0196] According to the present invention, production of L-amino acids such as branched-chain L-amino acids by a bacterium of the family *Enterobacteriaceae* can be improved.

EP 3 098 319 A1

SEQUENCE LISTING

<110> Ajinomoto Co., Inc.

<120> A METHOD FOR PRODUCING AN L-AMINO ACID USING A BACTERIUM OF THE FAMILY ENTEROBACTERIACEAE HAVING AN ATTENUATED EXPRESSION OF A gshA GENE

<130> D691-16071

<150> RU2015120052

<151> 2015-05-28

<160> 9

<170> PatentIn version 3.5

<210> 1

<211> 1557

<212> DNA

<213> Escherichia coli

<400> 1

```

ttgatcccg acgtatcaca ggcgctggcc tggctggaaa aacatcctca ggcgttaaag      60
gggatacagc gtgggctgga gcgcgaaact ttgcgtgtta atgctgatgg cacactggca      120
acaacagggtc atcctgaagc attaggttcc gcaactgacgc acaaatggat tactaccgat      180
tttgcggaag cattgctgga attcattaca ccagtggatg gtgatattga acatatgctg      240
acctttatgc gcgatctgca tcgttatacg gcgcgcaata tgggcatga gcggatgtgg      300
ccgttaagta tgccatgcta catcgagaa ggtcaggaca tcgaactggc acagtacggc      360
acttctaaca ccggacgctt taaaacgctg tatcgtgaag ggctgaaaaa tcgctacggc      420
gcgctgatgc aaaccatttc cggcgtgcac tacaatttct ctttgccaat ggcattctgg      480
caagcgaagt gcggtgatat ctccggcgct gatgccaaag agaaaatttc tgcgggctat      540
ttccgcgtta tccgcaatta ctatcgtttc ggttgggtca ttccttatct gtttggtgca      600
tctccggcga tttgttcttc tttcctgcaa ggaaaaccaa cgctcgctgcc gtttgagaaa      660
accgagtgcg gtatgtatta cctgccgtat gcgacctctc ttcgtttgag cgatctcggc      720
tataccaata aatcgcaaag caatcttggt attaccttca acgatcttta cgagtacgta      780
gcgggcctta aacaggcaat caaaacgcca tcggaagagt acgcgaagat tggatttgag      840
aaagacggta agaggctgca aatcaacagc aacgtgttgc agattgaaaa cgaactgtac      900
gcgccgattc gtccaaaacg cgttaccgcg agcggcgagt cgccttctga tgcgctgtta      960
cgtggcggca ttgaatatat tgaagtgcgt tcgctggaca tcaaccctgt ctcccgatt      1020
ggtgtagatg aacagcaggt gcgattcctc gacctgttta tggctctggg tgcgctggct      1080
gatgcaccgg aaatgagcag tagcgaactt gcctgtacac gcgttaactg gaaccgggtg      1140
atcctcgaag gtcgcaaacc gggctcgacg ctgggtatcg gctgcgaaac cgcacagttc      1200
ccgttaccgc aggtgggtaa agatctgttc cgcgatctga aacgcgtcgc gcaaacgctg      1260
gatagtatta acggcggcga agcgtatcag aaagtgtgtg atgaactggg tgcctgcttc      1320
gataatcccg atctgacttt ctctgccgct atcttaaggt ctatgattga tactggtatt      1380
ggcggaacag gcaaagcatt tgcagaagcc taccgtaatc tgctgcgtga agagccgctg      1440
gaaattctgc gcgaagagga tttttagacc gagcgcgagg cgtctgaacg ccgtcagcag      1500
gaaatggaag ccgctgatac cgaaccgttt gcggtgtggc tggaaaaaca cgcctga      1557

```

<210> 2

<211> 518

<212> PRT

<213> Escherichia coli

<400> 2

```

Met Ile Pro Asp Val Ser Gln Ala Leu Ala Trp Leu Glu Lys His Pro
1           5           10           15
Gln Ala Leu Lys Gly Ile Gln Arg Gly Leu Glu Arg Glu Thr Leu Arg
20           25           30
Val Asn Ala Asp Gly Thr Leu Ala Thr Thr Gly His Pro Glu Ala Leu
35           40           45

```

EP 3 098 319 A1

	Gly	Ser	Ala	Leu	Thr	His	Lys	Trp	Ile	Thr	Thr	Asp	Phe	Ala	Glu	Ala
	50						55					60				
	Leu	Leu	Glu	Phe	Ile	Thr	Pro	Val	Asp	Gly	Asp	Ile	Glu	His	Met	Leu
	65					70					75					80
5	Thr	Phe	Met	Arg	Asp	Leu	His	Arg	Tyr	Thr	Ala	Arg	Asn	Met	Gly	Asp
					85					90					95	
	Glu	Arg	Met	Trp	Pro	Leu	Ser	Met	Pro	Cys	Tyr	Ile	Ala	Glu	Gly	Gln
				100					105					110		
	Asp	Ile	Glu	Leu	Ala	Gln	Tyr	Gly	Thr	Ser	Asn	Thr	Gly	Arg	Phe	Lys
			115					120					125			
10	Thr	Leu	Tyr	Arg	Glu	Gly	Leu	Lys	Asn	Arg	Tyr	Gly	Ala	Leu	Met	Gln
	130						135					140				
	Thr	Ile	Ser	Gly	Val	His	Tyr	Asn	Phe	Ser	Leu	Pro	Met	Ala	Phe	Trp
	145					150					155					160
	Gln	Ala	Lys	Cys	Gly	Asp	Ile	Ser	Gly	Ala	Asp	Ala	Lys	Glu	Lys	Ile
				165						170					175	
15	Ser	Ala	Gly	Tyr	Phe	Arg	Val	Ile	Arg	Asn	Tyr	Tyr	Arg	Phe	Gly	Trp
			180						185					190		
	Val	Ile	Pro	Tyr	Leu	Phe	Gly	Ala	Ser	Pro	Ala	Ile	Cys	Ser	Ser	Phe
			195					200					205			
	Leu	Gln	Gly	Lys	Pro	Thr	Ser	Leu	Pro	Phe	Glu	Lys	Thr	Glu	Cys	Gly
20			210				215					220				
	Met	Tyr	Tyr	Leu	Pro	Tyr	Ala	Thr	Ser	Leu	Arg	Leu	Ser	Asp	Leu	Gly
	225					230					235					240
	Tyr	Thr	Asn	Lys	Ser	Gln	Ser	Asn	Leu	Gly	Ile	Thr	Phe	Asn	Asp	Leu
				245						250					255	
25	Tyr	Glu	Tyr	Val	Ala	Gly	Leu	Lys	Gln	Ala	Ile	Lys	Thr	Pro	Ser	Glu
			260						265					270		
	Glu	Tyr	Ala	Lys	Ile	Gly	Ile	Glu	Lys	Asp	Gly	Lys	Arg	Leu	Gln	Ile
			275					280					285			
	Asn	Ser	Asn	Val	Leu	Gln	Ile	Glu	Asn	Glu	Leu	Tyr	Ala	Pro	Ile	Arg
			290			295						300				
30	Pro	Lys	Arg	Val	Thr	Arg	Ser	Gly	Glu	Ser	Pro	Ser	Asp	Ala	Leu	Leu
	305					310					315					320
	Arg	Gly	Gly	Ile	Glu	Tyr	Ile	Glu	Val	Arg	Ser	Leu	Asp	Ile	Asn	Pro
				325						330					335	
	Phe	Ser	Pro	Ile	Gly	Val	Asp	Glu	Gln	Gln	Val	Arg	Phe	Leu	Asp	Leu
				340				345						350		
35	Phe	Met	Val	Trp	Cys	Ala	Leu	Ala	Asp	Ala	Pro	Glu	Met	Ser	Ser	Ser
			355					360					365			
	Glu	Leu	Ala	Cys	Thr	Arg	Val	Asn	Trp	Asn	Arg	Val	Ile	Leu	Glu	Gly
			370				375					380				
	Arg	Lys	Pro	Gly	Leu	Thr	Leu	Gly	Ile	Gly	Cys	Glu	Thr	Ala	Gln	Phe
	385					390					395					400
40	Pro	Leu	Pro	Gln	Val	Gly	Lys	Asp	Leu	Phe	Arg	Asp	Leu	Lys	Arg	Val
				405						410					415	
	Ala	Gln	Thr	Leu	Asp	Ser	Ile	Asn	Gly	Gly	Glu	Ala	Tyr	Gln	Lys	Val
				420					425					430		
	Cys	Asp	Glu	Leu	Val	Ala	Cys	Phe	Asp	Asn	Pro	Asp	Leu	Thr	Phe	Ser
			435					440					445			
45	Ala	Arg	Ile	Leu	Arg	Ser	Met	Ile	Asp	Thr	Gly	Ile	Gly	Gly	Thr	Gly
			450				455					460				
	Lys	Ala	Phe	Ala	Glu	Ala	Tyr	Arg	Asn	Leu	Leu	Arg	Glu	Glu	Pro	Leu
						470					475					480
50	Glu	Ile	Leu	Arg	Glu	Glu	Asp	Phe	Val	Ala	Glu	Arg	Glu	Ala	Ser	Glu
						485				490					495	
	Arg	Arg	Gln	Gln	Glu	Met	Glu	Ala	Ala	Asp	Thr	Glu	Pro	Phe	Ala	Val
				500					505					510		
	Trp	Leu	Glu	Lys	His	Ala										
			515													
55																
	<210>	3														

<211> 63
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer P1

<400> 3
 ccctgaattc agagatgaaa ttttggccac tcacgtgaag cctgcttttt tataactaagt 60
 tgg 63

<210> 4
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer P2

<400> 4
 tgcacatatg gtcaccatta cagttatgct aattaacgct caagttagta taaaaaagct 60
 gaac 64

<210> 5
 <211> 1378
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR-product 1

<400> 5
 ccctgaattc agagatgaaa ttttggccac tcacgtgaag cctgcttttt tataactaagt 60
 tggcattata aaaagcattg cttatcaatt tgttgcaacg aacaggtcac tatcagtcac 120
 aataaaatca ttatttgatt tcgtcgagtt acgccccgcc ctgccactca tcgcagtact 180
 gttgtaattc attaaagcatt ctgccgacat ggaagccatc acagacggca tgatgaacct 240
 gaatcgccag cggcatcagc accttgcgc cttgcgtata atatttgccc atgggtgaaa 300
 cgggggcgaa gaagttgtcc atattggcca cgtttaaatc aaaactgggtg aaactcacc 360
 agggattggc tgagacgaaa aacatattct caataaacc tttagggaaa taggccagg 420
 tttcaccgta acacgccaca tcttgcgaa atgtgtgtag aaactgccgg aaatcgctcg 480
 ggtattcact ccagagcgat gaaaacgttt cagtttgctc atggaaaacg gtgtaacaag 540
 ggtgaacact atcccatatc accagctcac cgtctttcat tgccatacgg aattccggat 600
 gagcattcat caggcgggca agaattgtgaa taaaggccgg ataaaacttg tgcttatttt 660
 tctttacggc ctttaaaaag gccgtaatat ccagctgaac ggtctgggta taggtacatt 720
 gagcaactga ctgaaatgcc tcaaaatgtt ctttacgatg ccattgggat atatcaacgg 780
 tggatatatc agtgattttt ttctccattt tagcttcctt agctcctgaa aatctcgata 840
 actcaaaaaa tacgcccggt agtgatctta tttcattatg gtgaaagtgt gaacctctta 900
 cgtgccgatc aacgtctcat tttcgccaaa agttggccca gggcttcccg gtatcaacag 960
 ggacaccagg atttattttat tctgcgaagt gatcttccgt cacaggattt tattcggcgc 1020
 aaagtgcgtc ggggtgatgct gccaaacttac tgatttagtg tatgatgggt tttttgaggt 1080
 gctccagtggt cttctgtttc tatcagctgt ccctcctgtt cagctactga cgggggtgggtg 1140
 cgtaacggca aaagcaccgc cggacatcag ctgcagctctg ttacagggtca ctaataccat 1200
 ctaagtagtt gattcatagt gactgcatat gttgtgtttt acagtattat gtagtctgtt 1260
 ttttatgcaa aatctaattt aatatattga ttttatatc attttacgtt tctcgttcag 1320
 cttttttata ctaacttgag cgtaattag cataactgta atgggtacca tatgtgca 1378

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Primer P3

<400> 6

agcgttacgc tatgttgacg

20

<210> 7

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer P4

<400> 7

ctttccaggc atcagcaaca

20

<210> 8

<211> 2155

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR-product 2

<400> 8

ctttccaggc	atcagcaaca	cgctgctcat	ctggcggtacc	aatcagactc	atataaaaaac	60
cggtgctggc	gcccattggc	gagatatcga	taatctctac	accattaccg	ttaagatggg	120
tacgcataaa	accagcaaac	aggtgctcca	gggtatggat	ccctctttct	ggcatcactt	180
ctttgttcgg	cacgcagaag	cgcagatcga	acacgggtgat	tgcgctcgcca	tgcggggtgt	240
tcattgtttt	cgccaccgga	actgcaggcg	cttccatccg	ggtatgatcg	actgtgaagc	300
tatctaacaa	cggtatttag	ccacctccgg	taatTTTTTT	aaaaattttc	tgaactcttt	360
cttcccaggc	gagtctgagt	atatgaaaga	cgcgcatttg	ttatcatcat	ccctgaattc	420
agagatgaaa	ttttggccac	tcacgagtgg	cctttttctt	ttctgtcagg	cgtgtttttc	480
cagccacacc	gcaaacggtt	cgttatcagc	ggcttccatt	tcctgctgac	ggcgttcaga	540
cgcctcgcgc	tcggctacaa	aatcctcttc	gcgccagaatt	tcagcgggt	cttcacgcag	600
cagattacgg	taggcttctg	caaagtcttt	gcctgttccg	ccaataccag	tatcaatcat	660
agaccttaag	atacgggcag	agaaagtcag	atcgggatta	tcgaagcagg	caaccagttc	720
atcacacact	ttctgatacg	cttcgcccgc	gttaatacta	tcagcgtttt	gcgcgacgcg	780
tttcagatcg	cggaacagat	ctttacccac	ctgcggtaac	gggaactgtg	cgttttcgca	840
gccgataccc	agcgtcagac	ccggtttgcg	accttcgagg	atcaccgggt	tccagttaac	900
gcgtgtacag	gcaagtctgc	tactgctcat	ttccgggtgca	tcagccagcg	cacaccagac	960
cataaacagg	tcgaggaatc	gcacctgctg	ttcatctaca	ccaatcggcg	agaacgggtt	1020
gatgtccagc	gaacgcactt	caatatattc	aatgccgcca	cgtaacagcg	catcagaagg	1080
cgactcgccg	ctgcgggtaa	cgcgttttgg	acgaatcggc	gcgtacagtt	cgtttttcaat	1140
ctgcaacacg	ttgctgttga	tttgacgcct	cttacggctc	ttctcaatac	caatcttcgc	1200
gtactcttcc	gatggcggtt	tgattgctcg	tttaaggccc	gctacgtact	cgtaaaagtc	1260
gttgaaggta	ataccaagat	tgctttgcca	tttattggta	tagccgagat	cgctcaaacg	1320
aagagaggtc	gcatacggca	ggttaatacat	accgcaactc	gtttttctcaa	acggcagcga	1380
cgttggtttt	ccttgacgga	aagaagaaca	aatcgccgga	gatgcaccaa	acagataagg	1440
aatgacccaa	ccgaaacgat	agtaattgct	gataacgcgg	aaatagcccg	cagaaatttt	1500
ctcttttgca	tcagcgcccg	agatatcacc	gcacttoget	tgccagaatg	ccattggcaa	1560
agagaaattg	tagtgacgac	cggaaatggt	ttgcatcagc	gcgccgtagc	gattttttcag	1620
cccttcacga	tacagcggtt	taaagcgctc	gggtgttagaa	gtgccgtact	gtgccagttc	1680
gatgtcctga	ccttctgcga	tgtagcatgg	catacttaac	ggccacatcc	gctcatcgcc	1740
catattgcgc	gccgtataac	gatgcagatc	gcgcataaag	gtcagcatat	gttcaatatc	1800
accatccact	ggtgtaatga	attccagcaa	tgcttccgca	aaatcggtag	taatccattt	1860
gtgcgtcagt	gcggaacctc	atgcttcagg	atgacctgtt	gttgccagtg	tgccatcagc	1920
attaacacgc	aaagtttcgc	gctccagccc	acgctgtatc	ccctttaacg	cctgaggatg	1980
tttttccagc	caggccagcg	cctgtgatac	gtccgggatc	aaattgacct	cccgcctgtc	2040

aaaatcgttt taattagcat aactgtaatg gtgaccatat gtgcaggcct acaattagtg 2100
ccaccacatc atgccctgaa cggtcgctgc tgcaactgca acatagcgta acgct 2155

<210> 9
<211> 1858
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR-product 3

<400> 9
ctttccaggc atcagcaaca cgctgctcat ctggcgtagc aatcagactc atataaaaac 60
cggtgcggca gccattggc gagatatcga taatctctac accattaccg ttaagatggt 120
tacgcataaa accagcaaac aggtgctcca gggtaggat cctcttttct ggcattcactt 180
ctttgttcgg cacgcagaag cgcagatcga acacggtagt tgcgtcgcca tgcggggtgt 240
tcattgtttt cgccaccgga actgcaggcg cttccatccg ggtatgatcg actgtgaagc 300
tatctaacaa cggcatttag ccacctccgg taatTTTTTT aaaaattttc tgaactcttt 360
cttcccaggc gagtctgagt atatgaaaga cgcgcatttg ttatcatcat ccctgaattc 420
agagatgaaa ttttggccac tcacgtgaag cctgcttttt tataactaagt tggcattata 480
aaaagcattg cttatcaatt tgttgcaacg aacaggtcac tatcagtcaa aataaaatca 540
ttatttgatt tcgtcgagtt acgccccgc ctgccactca tcgcagtact gttgtaattc 600
attaagcatt ctgccgacat ggaagccatc acagacggca tgatgaacct gaatcgccag 660
cggcatcagc accttgtcgc cttgcgtata atatttggcc atggtgaaaa cgggggcgaa 720
gaagttgtcc atattggcca cgtttaaatc aaaactggtg aaactcacc agggattggc 780
tgagacgaaa aacatattct caataaacc tttagggaaa taggccagg tttcaccgta 840
acacgccaca tcttgcgagt atatgtgtag aaactgccgg aaatcgctcg ggtattcact 900
ccagagcgat gaaaacgttt cagtttgctc atggaaaacg gtgtaacaag ggtgaacact 960
atcccatatc accagctcac cgtctttcat tgccatacgg aattccggat gagcattcat 1020
caggcgggca agaattgtgaa taaaggccgg ataaaacttg tgcttatttt tctttacggt 1080
ctttaaaaag gccgtaatat ccagctgaac ggtctgggta taggtacatt gagcaactga 1140
ctgaaatgcc tcaaaatgtt ctttacgatg ccattgggat atatcaacgg tggatatatcc 1200
agtgattttt ttctccattt tagcttcctt agctcctgaa aatctcgata actcaaaaaa 1260
tacgcccggg agtgcattta tttcattatg gtgaaagttg gaacctctta cgtgccgatc 1320
aacgtctcat tttcgccaaa agttggccca gggcttccc gtatcaacag ggacaccagg 1380
atattattat tctgcgaagt gatcttccgt cacaggtagt tattcggcgc aaagtgcgtc 1440
gggtgatgct gccaaacttac tgatttagtg tatgatgggt tttttgaggt gctccagtgg 1500
cttctgtttc tatcagctgt cctcctgtt cagctactga cggggtgggt cgtaacggca 1560
aaagcaccgc cggacatcag ctgcagctcg ttacagggtc ctaataccat ctaagtagtt 1620
gattcatagt gactgcatat gttgtgtttt acagtattat gtagtctgtt ttttatgcaa 1680
aatctaattt aatatattga tatttatatc attttacgtt tctcgttcag cttttttata 1740
ctaacttgag cgtaatttag cataactgta atggtgacca tatgtgcagg cctacaatta 1800
gtgccaccac atcatgccct gaacgggtcgc tgctgcaact gcaacatagc gtaacgct 1858

Claims

1. A method for producing an L-amino acid comprising:

- (i) cultivating an L-amino acid-producing bacterium of the family *Enterobacteriaceae* in a culture medium to produce the L-amino acid in the culture medium, the bacterial cells, or both; and
(ii) collecting said L-amino acid from the culture medium, the bacterial cells, or both,

wherein said bacterium has been modified to attenuate expression of a *gshA* gene.

2. The method according to claim 1, wherein said bacterium belongs to the genus *Escherichia*.

3. The method according to claim 2, wherein said bacterium is *Escherichia coli*.

4. The method according to claim 1, wherein said bacterium belongs to the genus *Pantoea*.
5. The method according to claim 4, wherein said bacterium is *Pantoea ananatis*.
- 5 6. The method according to any one of claims 1 to 5, wherein said expression of the *gshA* gene is attenuated due to inactivation of the *gshA* gene.
7. The method according to claim 6, wherein said *gshA* gene is deleted.
- 10 8. The method according to any one of claims 1 to 7, wherein said *gshA* gene is selected from the group consisting of:
 - (A) a DNA comprising the nucleotide sequence of SEQ ID NO: 1;
 - (B) a DNA comprising a variant nucleotide sequence of SEQ ID NO: 1 due to the degeneracy of the genetic code;
 - (C) a DNA having an identity of not less than 60% with respect to the entire nucleotide sequence of SEQ ID
 - 15 NO: 1, and wherein said DNA encodes a protein having an activity of γ -glutamate-cysteine ligase;
 - (D) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2; and
 - (E) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2, but which includes one or more mutations comprising substitution, deletion, insertion, or addition of one or several amino acid residues, and wherein said protein has the activity of γ -glutamate-cysteine ligase.
 - 20 (F) a DNA encoding a protein having an identity of not less than 65% with respect to the entire amino acid sequence of SEQ ID NO: 2, wherein said protein has the activity of γ -glutamate-cysteine ligase.
9. The method according to any one of claims 1 to 8, wherein said L-amino acid is selected from the group consisting of an aromatic L-amino acid and a non-aromatic L-amino acid.
- 25 10. The method according to claim 9, wherein said aromatic L-amino acid is selected from the group consisting of L-phenylalanine, L-tryptophan, and L-tyrosine.
11. The method according to claim 9, wherein said non-aromatic L-amino acid is selected from the group consisting of
- 30 L-alanine, L-arginine, L-asparagine, L-aspartic acid, L-citrulline, L-cysteine, L-glutamic acid, L-glutamine, glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-ornithine, L-proline, L-serine, L-threonine, and L-valine.
12. The method according to any one of claims 1 to 8, wherein said L-amino acid is a branched-chain L-amino acid.
- 35 13. The method according to claim 12, wherein said branched-chain L-amino acid is selected from the group consisting of L-isoleucine, L-leucine, and L-valine.
14. The method according to claim 13, wherein said L-amino acid is L-valine.



EUROPEAN SEARCH REPORT

 Application Number
 EP 16 17 1303

5

10

15

20

25

30

35

40

45

50

55

2

EPO FORM 1503 03.82 (P04C01)

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	DATABASE EPODOC [Online] EUROPEAN PATENT OFFICE, THE HAGUE, NL; 15 September 2010 (2010-09-15), "Escherichia coli and method for preparing L-cysteine by using same", XP002762089, Database accession no. CN-201010136361-A * abstract *	1-7,9-13	INV. C12P13/04 C12P13/08 C12N9/00
Y		8	
A	& CN 101 831 397 A (HANGZHOU BIOKING BIOCHEMICAL ENGINEERING CO LTD) 15 September 2010 (2010-09-15) -----	14	
Y	DATABASE UniProt [Online] 27 May 2015 (2015-05-27), "RecName: Full=Glutamate--cysteine ligase", XP002762090, retrieved from EBI accession no. UNIPROT:M9E1R3 Database accession no. M9E1R3 * 100% identical to SEQ ID NO:2; the whole document *	8	
A		14	TECHNICAL FIELDS SEARCHED (IPC) C12P C12N
X	----- CALHOUN K A ET AL: "Total amino acid stabilization during cell-free protein synthesis reactions", JOURNAL OF BIOTECHNOLOGY, vol. 123, no. 2, 17 May 2006 (2006-05-17), pages 193-203, XP024956805, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL ISSN: 0168-1656, DOI: 10.1016/J.JBIOTEC.2005.11.011 [retrieved on 2006-05-17] * the whole document *	1-7,9-13	
Y		8	
A	----- -/-	14	
The present search report has been drawn up for all claims			
Place of search Berlin		Date of completion of the search 20 September 2016	Examiner Schneider, Patrick
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



EUROPEAN SEARCH REPORT

Application Number
EP 16 17 1303

5

10

15

20

25

30

35

40

45

50

55

2

EPO FORM 1503 03.02 (P04C01)

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	WO 2006/138322 A2 (UNIV LELAND STANFORD JUNIOR [US]; CALHOUN KARA ANNE [US]; SWARTZ JAMES) 28 December 2006 (2006-12-28) * paragraphs [0012], [0023]; claim 10 *	1-7,9-13	
Y		8	
A		14	
X	EP 2 336 347 A1 (AJINOMOTO KK [JP]) 22 June 2011 (2011-06-22) * paragraph [0077] *	1-7,9-13	
Y		8	
			TECHNICAL FIELDS SEARCHED (IPC)
The present search report has been drawn up for all claims			
Place of search Berlin		Date of completion of the search 20 September 2016	Examiner Schneider, Patrick
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 16 17 1303

5 This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-09-2016

	Patent document cited in search report		Publication date		Patent family member(s)		Publication date
10	WO 2006138322	A2	28-12-2006	AU	2006259543 A1		28-12-2006
15				CA	2611908 A1		28-12-2006
				EP	1893768 A2		05-03-2008
				US	2007004001 A1		04-01-2007
				WO	2006138322 A2		28-12-2006

	EP 2336347	A1	22-06-2011	BR	PI0918299 A2		18-08-2015
20				CN	102177246 A		07-09-2011
				EP	2336347 A1		22-06-2011
				JP	5598329 B2		01-10-2014
				KR	20110074521 A		30-06-2011
				PE	03692011 A1		24-06-2011
				US	2011212496 A1		01-09-2011
25				WO	2010027045 A1		11-03-2010

30							
35							
40							
45							
50							
55							

ORM P0459

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4278765 A [0003] [0049]
- US 20060216796 A1 [0003]
- WO 9615246 A1 [0003]
- WO 9516042 A1 [0003]
- EP 0685555 A1 [0003]
- US 4346170 A [0003] [0065]
- US 5661012 A [0003]
- US 6040160 A [0003] [0066] [0072]
- CN 101831397 A [0005]
- US 2002058315 A1 [0042]
- RU 2215783 C2 [0042] [0045]
- EP 1170358 A1 [0042] [0148] [0175]
- EP 1170361 A1 [0042]
- JP 56106598 A [0044]
- EP 1170361 B1 [0045]
- US 6790647 B2 [0045]
- RU 2264459 C2 [0045]
- EP 2133417 A1 [0045]
- US 2009286290 A1 [0045]
- US 6218168 B1 [0048] [0153] [0154]
- RU 2279477 C2 [0048]
- US 5972663 A [0048] [0153]
- JP 11155571 A [0048]
- WO 0127307 A1 [0048]
- EP 1172433 A1 [0049] [0078] [0155]
- EP 1078989 A2 [0051]
- EP 955368 A2 [0051]
- EP 952221 A2 [0051]
- US 5378616 A [0052]
- US 5573945 A [0052]
- US 5908768 A [0054]
- US 5393671 A [0054]
- US 6110714 A [0054]
- US 6596517 B [0055]
- US 6331419 B1 [0056]
- RU 2003677 C1 [0058] [0060]
- RU 2119536 C1 [0058] [0060] [0061] [0160]
- US 4388405 A [0058]
- US 6344347 B1 [0058]
- EP 1085087 A2 [0058]
- US 6258554 B1 [0058]
- JP 56005099A B [0061]
- EP 1016710 A2 [0061] [0097]
- RU 2119536 [0061]
- JP 5304969 A [0062]
- JP 5130882 A [0062]
- JP 2000458 A [0062]
- EP 0356739 A1 [0062]
- US 5998178 A [0062] [0094]
- US 6124121 A [0063] [0165]
- JP 62034397 B [0063]
- JP 8070879 A [0063]
- WO 9606926 A [0063]
- US 6403342 B1 [0064]
- EP 1239041 A2 [0064] [0078] [0137]
- EP 1253195 A1 [0066]
- EP 1170376 A1 [0066]
- US 5830716 A [0066]
- WO 2005073390 A [0066]
- US 5932453 A [0066]
- WO 9523864 A [0067]
- WO 9617930 A [0067]
- WO 2005010175 A [0067]
- WO 2006078039 A [0068] [0069]
- US 5827698 A [0069] [0070]
- GB 2075055 A [0074]
- RU 2209248 C2 [0074]
- RU 2215782 C2 [0074]
- JP 2000139471 A [0074]
- US 5354672 A [0077]
- KR 8903681 [0077]
- US 4407952 A [0077]
- EP 488424 B1 [0077]
- US 7259003 B [0077]
- US 7666655 B [0077]
- DE 3127361 A1 [0078] [0079]
- GB 2075056 A [0079]
- RU 2207371 C2 [0079]
- US 5175107 A [0080] [0110]
- US 5705371 A [0080] [0087]
- US 5631157 A [0080]
- US 5939307 A [0080]
- US 5474918 A [0080]
- US 5376538 A [0080]
- EP 1149911 A2 [0080]
- EP 0593792 A1 [0080]
- WO 2005049808 A1 [0086]
- WO 2003097839 A1 [0086]
- US 5756345 A [0091]
- US 6180373 B1 [0091] [0192]
- US 4371614 A [0091] [0093]
- WO 9708333 A [0091]
- US 6319696 B1 [0091]
- US 2003148473 A1 [0091]
- US 2003157667 A1 [0091]
- WO 9408031 A1 [0092]
- JP 5771397A B [0093]
- JP 62244382 A [0093]

- WO 2005103275 A [0093]
- US 5658766 A [0095] [0097]
- WO 9606926 A1 [0096]
- EP 1942183 B1 [0097]
- US 4391907 A [0097]
- WO 9534672 A [0103]
- WO 0018935 A1 [0109]
- US 5431933 A [0131]
- JP 1214636 A [0131]
- US 4956471 A [0131]
- JP 4777051 B [0131]
- JP 4946654 B [0131]
- JP 5840358 B [0131]
- JP 6238714 B [0131]
- US 20050025878 A [0131]
- JP 2008099668 A [0133]
- EP 1942183 A1 [0133]
- WO 05010175 A [0148] [0175]
- JP 3032013 B [0192]
- EP 0662143 B1 [0192]

Non-patent literature cited in the description

- **APONTOWEIL P. ; BERENDS W.** Glutathione biosynthesis in *Escherichia coli* K 12. Properties of the enzymes and regulation. *Biochim. Biophys. Acta*, 1975, vol. 399 (1), 1-9 [0005]
- **BACHMANN, B.J.** *Derivations and genotypes of some mutant derivatives of E. coli K-12*, 2460-2488 [0039]
- *E. coli* and *Salmonella*: cellular and molecular biology. ASM Press, 1996 [0039]
- **DOROSHENKO V.G. et al.** The directed modification of *Escherichia coli* MG1655 to obtain histidine-producing mutants. *Prikl. Biochim. Mikrobiol. (Russian)*, 2013, vol. 49 (2), 149-154 [0061] [0160]
- **BLOOM F.R. et al.** *The 15th Miami winter symposium*, 1983, 34 [0079]
- **GUSYATINER M. et al.** *Genetika (Russian)*, 1978, vol. 14, 947-956 [0080]
- **YU D. et al.** *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97 (11), 5978-5983 [0102]
- **DATSENKO K.A. ; WANNER B.L.** *Proc. Natl. Acad. Sci. USA*, 2000, vol. 97 (12), 6640-6645 [0102] [0110] [0133] [0134] [0148] [0175]
- **ZHANG Y. et al.** *Nature Genet.*, 1998, vol. 20, 123-128 [0102]
- **CARRIER T.A. ; KEASLING J.D.** *Biotechnol. Prog.*, 1999, vol. 15, 58-64 [0103]
- *Methods Enzymol.*, 1985, vol. 113, 379-390 [0108]
- *Proc. Natl. Acad. Sci. USA*, 1977, vol. 74 (8), 3330-3334 [0108]
- **GEGG M.E. et al.** Determination of glutamate-cysteine ligase (gamma-glutamylcysteine synthetase) activity by high-performance liquid chromatography and electrochemical detection. *Anal. Biochem.*, 2002, vol. 304 (1), 26-32 [0108]
- **BRADFORD M.M.** *Anal. Biochem.*, 1976, vol. 72, 248-254 [0108]
- **GOLDSTEIN M.A. ; DOI R.H.** Prokaryotic promoters in biotechnology. *Biotechnol. Annu. Rev.*, 1995, vol. 1, 105-128 [0109]
- **SAMBROOK J. ; FRITSCH E.F. ; MANIATIS T.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0112] [0135]
- **GREEN M.R. ; SAMBROOK J.R.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 2012 [0112]
- **BERNARD R. GLICK ; JACK J. PASTERNAK ; CHERYL L. PATTEN.** *Molecular Biotechnology: principles and applications of recombinant DNA*. ASM Press, 2009 [0112]
- **KARLIN S. ; ALTSCHUL S.F.** Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes. *Proc. Natl. Acad. Sci. USA*, 1990, vol. 87, 2264-2268 [0118]
- Applications and statistics for multiple high-scoring segments in molecular sequences. *Proc. Natl. Acad. Sci. USA*, 1993, vol. 90, 5873-5877 [0118]
- **PEARSON W.R.** Rapid and sensitive sequence comparison with FASTP and FASTA. *Methods Enzymol.*, 1990, vol. 183, 63-98 [0118]
- **CLUSTAL W.** improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. *Nucleic Acids Res.*, 1994, vol. 22, 4673-4680 [0118]
- **LEWIN B.** *Genes VIII*. Pearson Education, Inc, 2004 [0120]
- **WHITE T.J. et al.** *The polymerase chain reaction, Trends Genet.*, 1989, vol. 5, 185-189 [0122]
- **SAMBROOK J. ; RUSSELL D.W.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 2001 [0135] [0161] [0166] [0188]
- **SAMBROOK J. et al.** *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press, 1989 [0135]
- **MILLER J.H.** *Experiments in Molecular Genetics*. Cold Spring Harbor Lab. Press, 1972 [0137]